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ABSTRACT OF DISSERTATION

NEW SINGLE MOLECULE IN VIVO AND EX VIVO METHODS TO
UNDERSTAND THE PHYSIOLOGICAL EFFECTS OF NICOTINE USE
The consumption of tobacco products leads to several health risks, including
respiratory diseases, cardiovascular diseases, and many different cancers. Nicotine, the
primary addictive compound in tobacco, acts on the cholinergic system through
nicotinic acetylcholine receptors (nAChRs), which is believed to be an essential
component of addiction. However, the lack of a complete understanding of the
neurobiological mechanisms of nicotine abuse is one of the primary barriers to finding
potent therapeutics for smoking cessation. Single-molecule imaging is an ideal tool to study
molecular mechanisms of protein and physiological changes both in vitro and in vivo. In
this dissertation, our research efforts focused on the discovery of novel single-molecule
imaging tools that aid in understanding the physiological changes related to nicotine
addiction.
Specifically, we studied 1) membrane receptor assembly. We developed an
innovative ex vivo approach that enables brain region specific single-molecule imaging to
monitor the distribution of α4β2 nAChR assembly during nicotine exposure and
withdrawal. This work reveals the selectivity of nicotine-induced upregulation in different
brain regions in live animals. 2) characterization of nanovesicles derived from cells. We
developed a high throughput fluorescence correlation spectroscopy (ht-FCS) approach that
enables the rapid characterization of vesicle surface proteins. Characterized vesicles could
either be explored as therapeutic delivery vehicles or be used to study membrane receptors.
3) blood flow properties. We demonstrated the application of multiphoton in vivo
fluorescence correlation spectroscopy (FCS) for the measurement of cerebral blood flow
with high spatial and temporal resolution. The cerebrovascular dysfunction is potentially
linked to nicotine use disorder, blood-brain barrier (BBB) disruption, and gliovascular
coupling.

KEYWORDS: nicotine, nicotinic acetylcholine receptors, fluorescence microscopy,
single-molecule characterization, fluorescence correlation spectroscopy, blood flow
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INTRODUCTION
1.1

Nicotine
Smoking is one of the leading causes of death in our society. More than 7.1 million

people worldwide have died of diseases associated with tobacco consumption in 2016
alone [1]. Despite the significant decrease in production in recent decades, the U.S. is still
one of the top five tobacco-producing countries [2]. In the United States alone, it was
estimated that over 1,300 deaths were linked to smoking every day, leading to a total of
more than 490,000 deaths a year [3]. Even more concerning, there has been a dramatic
increase in the use of e-cigarettes among teenagers and young adults since 2017 [4].
Smoking harms almost every organ in the human body. It has been associated with many
diseases, including several types of cancers, respiratory diseases, ischemic heart diseases,
and stroke [5, 6]. Although numerous cessation treatments are available and most smokers
have a desire to quit, only about 8% could achieve complete abstinence [7]. One of the
primary barriers for smokers to stop is that nicotine causes addiction [8].
Nicotine is an alkaloid found in tobacco leaves. It is a clear liquid in its pure form
and turns to brown when exposed to air. The absorption of nicotine occurs orally in the
lungs, trans-dermally through the skin, or in the gut through different nicotine product
preparations (e.g., nicotine gums, vaping systems, patches) [9]. Although people have used
it for thousands of years, the cellular and physiological mechanisms related to brain
function and behavior were not reported until the mid-1990s. Considerable studies indicate
absorbed nicotine binds with high affinity to neuronal nicotinic acetylcholine receptors
(nAChRs), which are expressed through the central nervous system (CNS) and peripheral
nervous system (PNS) [10-12]. Despite the numerous deleterious effects on overall health,

nicotine has demonstrated long-term benefits in preventing neurodegenerative diseases,
like Parkinson's disease and Alzheimer's disease [13, 14]. Overall, the long-term use of
nicotine influences the cholinergic system through nAChRs, which cause addiction.
Despite the clear health risks associated with tobacco consumption, users perceive some
advantages such as the fact that the short-term administration of nicotine improves
cognitive function [15, 16].

1.2

Nicotinic acetylcholine receptors
Nicotinic acetylcholine receptors (nAChRs) belong to a Cys-loop ligand-gated ion

channel (LGIC) superfamily that includes the serotonin 5-HT3, GABAA, and glycine
receptors [17]. These receptors have three different states in response to agonists: opening
state with high-affinity for agonist binding, closing state with low-affinity for agonist
binding, and a desensitized state, which is nonconductive but a high-affinity state. Upon
acetylcholine (Ach) or other cholinergic agonist binding, the conformation of nAChRs
change to an open state, allowing for an influx of Na+, Ca2+, and efflux of K+ cations. Then
the receptor closes to a nonconducting state after several milliseconds to seconds [18].
Prolonged exposure to a low concentration of nicotine, however, renders the receptor
unresponsive to the agonist, and cation flux is also terminated [18, 19]. To better
understand the molecular mechanism of nAChR biology, including the response and
regulation by different external compounds, it is imperative to study the primary structure
and overall architecture of the receptor.

2

1.2.1 The structure and diversity of nAChRs
A fully assembled neuronal nAChR has a pentameric structure arranged around a
central hydrophilic pore, as shown in Figure 1.1a. It is composed from 9 alpha subunits (α2
to α10) and 3 beta subunits (β2 to β4) leading to a complex assembly of structures. Each
subunit has 4 transmembrane domains (M1 to M4), a relatively long extracellular Nterminal, a large intracellular cytoplasmic loop lines between M3 and M4, and a relatively
short extracellular C-terminal (Figure 1.1b) [18]. The M2 domain aligns along the central
conduction path with partial contribution from the M1 domain. The M4 domain is away
from the central pore, which interacts with the lipid bilayer. The M3 domain is located on
the opposite side of M1, which helps complete the helix bundle. The long extracellular Ndomain contains a Cys-loop, where Cys 128 and Cys 142 form a disulfide bond that is
separated by 13 amino acids to create a signature sequence of this ligand-gated ion channel
superfamily (Torpedo α1 subunit numbering). This Cys-loop may play a role in the
propagation of conformational changes from the extracellular domain and transmembrane
domain. The presence of the Cys-Cys pair near the entrance of M1 (Cys 192, 193, Torpedo
numbering) is vital for agonist binding, which is also the key to define the α- and non-αsubunits [20]. The intracellular domain lies between M3 and M4 and has a variable size in
different subunits. It is involved in subunit folding and receptor trafficking [21, 22]. The
canonical agonist binding site is a hydrophobic pocket formed at the interface between
adjacent subunits. The "positive" side of the binding site is produced by an α subunit,
whereas the back side, or "negative" side, is formed by adjacent non-α subunits with key
residues determining ligand selectivity [18].
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Neuronal nAChRs are homomeric or heteromeric combinations of 5 subunits
composed of 12 different subunit types with distinct pharmacological properties.
Homopentamers consist of 5 identical subunits with 5 ligand binding sites. For example,
α7-α9 subunits can form homomeric receptors. Among all these homomers, only α7 is
widely distributed in the mammalian brain [12]. Heteropentamers are the combination of
alternating α subunits and β subunits with two orthosteric agonist binding sites formed
between α and β subunits [23]. It usually contains at least two essential α subunits and two
essential β subunits. The fifth position can be an additional α or β subunit, or an auxiliary
subunit, such as α5 or β3 [24]. For instance, α4β2-containing receptors, the most abundant
nAChR subtype in the mammalian brain, can be expressed as (α4)3(β2)2, (α4)2(β2)3,
(α4)2(β2)2(α5), or (α4)2(β2)2(β3). The crystal structure of (α4)2(β2)3 shows the assembly of
heteromeric structures (Figure 1.1 c and d) [25]. The α5 and β3 subunits have been
described as only accessory subunits because they cannot form functional receptors by
pairwise combination with other subunits [26]. The traditional studies also showed that
these subunits do not take part in forming ACh binding sites. However, in recent studies,
it has been demonstrated that α5 and β3 subunits could form non-canonical binding sites
in α5/α4 and β3/α4 interfaces [27]. Interestingly, these unorthodox sites have shown unique
ligand selectivity. For example, MTSET could block this binding site to diminish the Ach
response of nAChRs containing these subunits, whereas NS9283 and sazetidine-A cannot
bind in the same site [27]. Furthermore, the α5 subunit in the α4β2 complex appears to
enhance receptor expression and facilitate channel closure [26].

4

Figure 1.1 Stucture of nAChRs.
a. Cartoon of pentameric structure of nAChR. b. A topography of a single subunit. c.
Crystal structure of α4β2 nAChR subtype. d. Perpendicular view of (α4)2(β2)3 crystal
structure from extracellular side to plasma membrane. α4 subunits are in green and β2
subunits in blue color.

(c and d: Morales-Perez CL, Noviello CM, & Hibbs RE, X-ray
structure of the human alpha4beta2 nicotinic receptor. Nature. 2016,
538(7625): 411-415. Copyright © 2016 Nature)
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Like the previous example of α4β2-containing receptors with (α4)3(β2)2 or
(α4)2(β2)3 expression, these heteropentamers containing only two types of subunits give
rise to the possibility of different stoichiometries. The assembly of different stoichiometries
leads to different receptor properties in terms of agonist binding affinity, expression, and
desensitization kinetics. While various studies concluded that the (α4)2(β2)3 is known as
the high-sensitivity (HS) receptor to agonist binding compared to the low-sensitivity (LS)
(α4)2(β2)3 subtype [28, 29], the LS α4β2 subtype shows a much higher permeability to
calcium [30]. The difference between these two isoforms is that the LS receptor has one
more non-canonical, α4(+)/(-)α4 binding site that has lower affinity to agonist binding than
the common α4(+)/(-)β2 binding site [31, 32]. The different binding sites appear to have a
different affinity to some pharmacological agonists. For example, NS9283 acts as a
selective agonist for binding at α4(+)/(-)α4 sites whereas Sazetidine-A has high affinity to
α4(+)/(-)β2 sites [33-35]. Receptors composed by α3 and β4 subunits also have two
stoichiometries showing that the different assembly exhibits the different sensitivity to
agonists [36, 37].
1.2.2 Significant nAChRs subtypes in the CNS
The current literature demonstrates that neuronal nAChRs modulate cholinergic
synaptic signaling in the CNS, especially the release of neurotransmitters from presynaptic
nAChRs [38]. The distinct genetic coding allows neuronal nAChRs to be expressed in
various neurons and some non-neuron cells [18, 39]. In the mammalian brain, α2-α7 and
β2-β4 subunits are widely expressed and distributed. Among them, α4, α7, and β2 are the
most common subunits expressed in the CNS. The α4β2* (* indicates the possibility that
other types of subunits are present) subtype is the predominant receptor subtype in the
6

CNS, comprising approximately 70% of all rodent CNS nAChRs [40]. This receptor is
believed to have a significant role in modulating the behavioral effects of nicotine [41].
This receptor subtype has also been demonstrated to be involved in cognition and attention
processing, such as memory and learning [42]. β2 knock-out (KO) mice show a decrease
in the behavioral effects of nicotine, including self-administration [43-45]. Therefore,
understanding the characteristics of α4β2* nAChRs with nicotine exposure in living
mammalian brains is particularly crucial for finding effective treatments for smoking
cessation. Another major subtype containing β2 subunits is the α6β2* nAChR, which are
found to be expressed in only a few mammalian brain regions, but are prevalent in the
mesostriatal and nigrostriatal dopaminergic systems. This subtype also has a high affinity
for nicotine and regulates the function of the mesostriatal dopamine (DA) pathway. Recent
studies have shown that α6β2* nAChRs are involved in nicotine elicited locomotion and
nicotine self-administration [46-49]. Given their restricted localization in mesostriatal DA
neurons, α6β2* receptors have generated interest as an attractive target for the treatment of
nicotine addiction and neurodegenerative disease. The α7 subtype is typically expressed as
a homomeric receptor with fast activation, fast desensitization, and high calcium
permeability properties [50]. It is the second most common subtype expressed throughout
the brain [40]. Unlike α4β2*, it has a low binding affinity to nicotine. However, Brunzell
et al. showed that decreased α7-mediated function might not only be linked to
schizophrenia but also to increased tobacco consumption [51].

1.3

Pharmacology of Nicotine
Nicotine is the major psychoactive component found in tobacco. For tobacco

smokers, nicotine is distilled from the burning tobacco and inhaled into the lungs, where it
7

is absorbed and rapidly enters the bloodstream and reaches the brain within 7 seconds [52].
The rapidity of absorption makes nicotine one of the most reinforcing and dependenceinducing substances of abuse. For smokeless tobacco products, nicotine is absorbed much
slower, but the peaks of blood nicotine levels are similar [53]. Once nicotine has entered
the brain, it binds to nAChRs and facilitates the release of many neurotransmitters,
including acetylcholine (ACh), dopamine (DA), γ-aminobutyric acid (GABA), glutamate,
and serotonin [54]. These neurotransmitters, in return, are believed to be mediating various
behaviors of nicotine. Besides in the brain, nicotine also accumulates in other organs, such
as the lungs, liver, kidneys, and even adipose tissues [55]. Nicotine is extensively
metabolized to cotinine by the liver enzyme Cytochrome P450 2A6 (CYP2A6) [56]. The
half-life of nicotine in body is about 2 hours, while cotinine is over 16 hours. This makes
cotinine a strong biomarker to correlate the frequency of nicotine exposure with risks of
various diseases [55]. Some other nicotine metabolites may be activated to carcinogens,
which contribute to the development of cancer (as mentioned in section 1.3.2) [57-59].
Nicotine dosage and the corresponding response is very complex. Low dose
nicotine stimulates neural systems, increases the heart rate and blood pressure, and
improves cognition functions. These effects make nicotine a sympathomimetic drug for
some cardiovascular diseases and neurodegenerative diseases. However, high dose
nicotine depresses neural systems which causes addiction, hypotension, and even
depression [54]. In addition, chronic nicotine exposure results in neuroadaptation, which is
highly associated with the upregulation of nAChRs. In summary, these pharmacological
effects make nicotine highly associated with addiction, different types of cancer, as well as
cardiovascular and cerebrovascular functions.
8

1.3.1 Nicotine and addiction
Similar to other drugs of abuse, nicotine stimulates the mesocorticolimbic
dopamine system, which has been recognized for its central mediator role in drug reward
and reinforcement [11]. The release of dopamine is vital for nicotine reinforcement
(nicotine self-administration). It is also facilitated by the release of glutamate, which could
be increased by exposure to nicotine [60, 61]. As stated in the last section, nAChRs are
expressed throughout the entire brain. DA neurons express several nAChRs subtypes
containing α4, α6, β2, β3, α3, and α5 subunits that bind nicotine with high affinity [11].
Some studies suggest that mice lacking the β2 subunits eliminate nicotine-mediated DA
release and block self-administration [49, 62]. Similarly, knock-out of α4 subunits in mice
abolishes nicotine self-administration and its long-term maintenance [49, 63].
Additionally, α6* nAChRs at the VTA (ventral tegmental area) also mediate nicotine selfadministration [46, 49]. From these studies, it is clear that the α4, α6, and β2 nAChRs are
involved in nicotine addiction. These results also indicate a complicated mechanism that is
tied to a variety of receptor subtypes and likely involves the assembly of specific receptor
stoichiometries.
Beyond the addictive effects caused by the release of neurotransmitters, one of the
earliest physiological changes related to nicotine exposure is the increased number of
nAChRs following chronic nicotine exposure. This phenomenon, termed nicotine-induced
upregulation, also includes changes in trafficking and stoichiometric assembly of the
receptors [64-66]. In fact, chronic nicotine exposure was shown to cause increases in [3H]nicotine binding in mouse brains [67], rat brain [68], and even human postmortem brains
[69, 70]. Ever since the linkage of nAChR upregulation with nicotine addiction was
9

established, considerable literature has implicated this phenomenon with various receptor
subtypes [71, 72], binding sites [31, 32, 34, 73], agonists [74-76], and localization of
receptors [39, 77]. At the same time, many different mechanisms for this phenomenon have
been proposed including increased subunit maturation [78-80], decreased subunit
degradation [81], trafficking to the cell surface [82-84], and conformation changes [85,
86]. However, the exact mechanism of this process is yet to be resolved.
The α4β2 subtype is the main nAChRs that contributes to nicotine addiction. The
upregulation of α4β2 nAChRs has been shown in clonal cell lines, cultured neurons, as
well as in animal models [65, 87-89]. There are multiple mechanisms that underlie this
phenomenon. One general agreement is that this process is posttranslational because
nicotine does not change the receptor subunit mRNA levels [90, 91]. Another commonly
accepted theory is the desensitization of receptors. Several studies reveal that receptors
undergo a long-lasting state with chronic nicotine exposure, resulting in much slower
kinetics of activation and desensitization [11]. Evidence shows that α4β2 nAChRs
expressed in human embryonic kidney (HEK) cells exhibit a decrease in calcium entry for
hours with 0.1-10 µM nicotine exposure [92]. Peng et al. shows that one mechanism
underlying the increase of plasma membrane receptors is that nicotine slows the turnover
of surface α4β2 nAChRs [93]. Mechanisms proposed for the effect of nicotine on receptor
trafficking include increasing the maturation of the subunits and assembly of receptors in
the ER [79, 88, 94], as well as enhancing the trafficking from ER to the cell plasma
membrane [83, 95]. The evidence gathered suggests nicotine acts as a pharmacological
chaperone at intracellular organelles to upregulate nAChRs, known as “inside-out”
pharmacology [84].
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An interesting finding in the study by Vallejo et al. shows that the nicotine induced
increase of [125I]-epibatidine binding at the surface of α4β2 nAChRs was not changed when
anterograde trafficking is blocked using brefeldin A [85]. The finding from this study has
been expanded by Govind et al [86], which shows that a transient upregulation occurs,
which may correspond to α4β2 nAChRs conformational changes. Expression of α4β2
nAChRs on mammalian cell lines also implies that nicotine has a preference to high
sensitivity (α4)2(β2)3 stoichiometry receptors [66, 96]. The most likely cause of this
phenomenon is that nicotine exposure slows the degradation of newly synthesized β2
subunits [86]. Recently published studies show both HS and LS α4β2 nAChRs are
presented in brain and the majority is the LS stoichiometry [97]. However, measurements
of the receptor stoichiometry changes in vivo have remained unclear. Here, in chapter 3,
we show a novel method that could measure the stoichiometry and distribution of α4β2
nAChRs in vivo.
Regardless of the pharmacologic actions of nicotine and associated mechanisms,
addiction to nicotine is related to relief of withdrawal symptoms, mental factors, and social
environments [54]. The administration of nicotine induces pleasure and improves
concentration. This phenomenon can be seen as a positive reinforcement of nicotine
addiction, while nicotine withdrawal causes depressed mood, anxiety, and stress [60].
1.3.2 Nicotine and cancer
In light of recent studies on smoking, it is becoming extremely difficult to ignore
the existence of many different types of cancer linked to smoking. Unlike with cigarette
smoking, nicotine has not been thought to be a direct carcinogen, but it can promote the
growth of tumors. However, the most recent literature has indicated that inhaled nicotine
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(or nitrosamines) might act as a direct carcinogen in the lungs [98, 99]. During the smoking
process, nicotine can be converted to different metabolites like cotinine, NNN (N'nitrosonornicotine), NNK (4-(metylnitrosamino)-1-(3-pyridyl)-1-butanon), and NNAL (4(metylnitrosamino)-1-(3-pyridyl)-1-butanol). The structure of nicotine and its metabolites
are shown in Figure 1.2. Similar to nicotine, these metabolites also bind to different
nAChRs. When nicotine is metabolized in the liver, approximately 70-80% of the nicotine
is converted into cotinine by the cytochrome P450 enzymes CYP2A6 and CYP2B6 [53].
The effects of cotinine have been reported as suppressors of cell apoptosis in human lung
adenocarcinoma A549 cells and promotors of tumor growth in the Lewis lung cancer
models [100]. NNN is derived from pure nicotine. It is a strong carcinogen that can lead to
the development of tumors and preferentially modulates tumor proliferation through α3
nAChRs [101]. NNK, more often presented after tobacco consumption, has been found to
upregulate α7 nAChRs and initiate lung tumors in A/J mice, but not the C3H mouse strain
[102, 103]. NNAL is a biomarker of NNK uptake, and itself is also proposed to be
associated with increased cancer risk [104].
Nicotine demonstrates genotoxicity effects. Cancer cells could still express
nAChRs and produce ACh. Nicotine at low concentration increases cell proliferation and
suppresses apoptosis in some types of cancer cells, such as colon cancer Caco-2 and HCT8 cells [56]. With the exposure of nicotine, nAChRs at the cell surface are activated, which
induced DNA damage via increased levels of reactive oxygen species (ROS) [105, 106].
Besides, co-incubation with nAChR antagonists resulted in a decrease in DNA damage
[105]. It has been reported that nicotine could decrease sensitivity and facilitate tumor
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Figure 1.2 Nicotine and its metabolites associated with tumor development.
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resistance to chemotherapy or radiotherapy through various stimulating pathways [107109]. For instance, nicotine increases the survival rate of H460 and A549 cells against
radiotherapy. This result can be reduced by exposure to α-bungarotoxin (α-BTX), an
inhibitor of α7 nAChRs [107]. Overall, nicotine has been shown to impact on cancer in
various ways, including increasing tumor growth, cell survival, suppressing tumor cell
apoptosis, and resistance to chemotherapy and radiotherapy.
1.3.3 Nicotine and cerebrovascular disorders
Despite the rising risk of cerebrovascular disorders like ischemic stroke in smokers,
there remains a paucity of evidence on the mechanistic connections of nicotine and
cerebrovascular functions. Changes in cerebral blood flow (CBF) are closely related to
physiological and pathological processes in substance abuse disorders. The effects of
nicotine, smoking, and smoking withdrawal on CBF are very complicated. The acute
administration of nicotine or cigarette smoking has shown to increase CBF; however, longterm cigarette smoking results in a reduction in CBF [110, 111]. Other studies, like
overnight withdrawal of nicotine among chronic tobacco smokers, have shown limited or
no effect on regional CBF [110]. The regulation of CBF is linked with transient neural
activity by neurovascular coupling [112]. As nicotine is the major pharmacologically active
component in tobacco and is involved in many neurobiological functions in the CNS, the
relationship between nicotine administration and cerebrovascular disorders (CVD) have
been proposed by many studies. Lines of evidence have shown that nicotine alters the
permeability of the blood-brain barrier (BBB) and disrupts the function of cerebral
endothelial cells [113-115]. BBB dysfunction has been suggested to be the fundamental
mechanism of small vessel disease, which is one of the essential causes of CVD and
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neurodegenerative diseases [116]. Surprisingly, accumulating pieces of evidence indicate
that stimulation of nAChRs may play a critical role in limiting inflammation and improving
neuroprotective functions under pathological conditions, which makes nAChR agonists
potential therapeutic drugs for CVD and neurodegenerative diseases [117].

1.4

Novel single-molecule methods in the study of biosystems
Fluorescence based techniques have been widely applied in biological and medical

studies in recent years. These methods allow precise measurements of single molecules in
cells, tissue, and even living organisms. By labeling with a variety of fluorescence probes
in proteins or subcellular components, fluorescence measurements can be exploited to
measure expression, kinetics and dynamics of a protein, monitor trafficking, and resolve
structures. Compared to traditional electrophysiological techniques, fluorescence detection
allows direct visualization of the micro activities of a physiological process, which helps
us further understand nicotine’s effects on complicated biological systems. However, the
heterogeneity of samples averages away the potential minor and anomalous details. The
transition states of a biological reaction can also be omitted from bulk measurements
(Figure 1.3) [118]. The use of single-molecule techniques has resolved this problem and
opens the door to a deeper understanding of the complex behavior of biological systems,
including molecular structure, dynamics, and function. In particular, single-molecule
fluorescence spectroscopy and microscopy offer the possibility to measure molecular
characteristics and interactions with high sensitivity and selectivity [119]. Thus, in this
work, to study changes caused by nicotine in nAChR assembly, we have chosen single
molecule fluorescence microscopy to reveal the detailed stoichiometric distributions
(Chapter 3).
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Figure 1.3 Illustration of the ensemble fluorescence detection and single molecule
fluorescence detection.
a, Fluorescence detection in ensemble represents the average value from many molecules
at different states. b, The detection of an individual molecule provides detailed information
about molecular properties, dynamics, and intermediate states.
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Single-molecule fluorescence microscopy (SMFM) is based on conventional
fluorescence microscopy. It allows us to look at individual molecules one at a time and
provide a high signal-to-noise ratio for visualization with detailed information for a
molecule of interest. There are two common strategies for single-molecule detection: one
is selectively exciting fluorescent molecules, like total internal reflection fluorescence
(TIRF) microscopy; the other is selectively collecting the emission signals from target
molecules, such as confocal microscopy [120]. Recent advances in single-molecule
fluorescence microscopy even render spatial resolution better than optical resolution limit,
such as different super-resolution microscopy techniques. Overall, these SMFM techniques
enhance our understanding of the trafficking behavior, conformational changes, and
mechanisms of individual molecules in biosystems in previously unimaginable detail.
Widely used techniques like single-molecule pull-down (SiMPull), which combines the
classical pull-down assay with single-molecule fluorescence imaging, also adds a
quantitative capability to study protein stoichiometry, interactions, and activities [121].
For single molecule spectroscopy (SMS), the major advantage is that it can reveal
the dynamics of single biological molecules. Fluorescence resonance energy transfer
(FRET) is one of the most commonly used techniques in the study of molecular
interactions, such as protein-protein and protein-nucleic acid interactions [122]. Another
commonly used SMS technique is fluorescence correlation spectroscopy (FCS). In this
technique, the transient fluorescence burst detected from solution yield multiple parameter
information, including solution viscosity, molecule size and concentration, diffusion
properties. Here, we have utilized this technique to characterize vesicle surface binding and
measure the flow rate in cerebral blood vessels (Chapter 4&5).
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1.4.1 Single-molecule pull-down
The functions of biomolecules in vivo are reflected in 1) conformational or
structural changes and 2) interactions with other biological molecules. There is a growing
body of literature that recognizes the importance of protein-protein interactions in
biosystems. Co-immunoprecipitation (Co-IP) and western blot are the most common
methods to study protein-protein interactions. However, the information obtained from
these methods lacks structural and dynamic details. Moreover, the free diffusion of many
small molecules makes the single-molecule detection very challenging. Thus, the
immobilization of single molecules at the surface becomes a new strategy to study dynamic
changes in molecular interactions. Recently, SiMPull [121] and other related methods
[123-126] combined with single-molecule fluorescent microscopy enable the observation
of protein-protein interactions in real-time at single molecule level.
Cell extracts like different protein complexes, and nucleic acids, could be
immobilized to the surface of imaging slides, as shown in Figure 1.4a. By using
biotinylated antibodies specific to the molecule of interests, the biocomplexes are
selectively pulled down to the avidin and biotin-PEG coated surface. The target molecules
are visualized either using fluorescent proteins or fluorophore tagged antibodies (Figure
1.4b and c). Combining with advanced single-molecule imaging techniques, such as total
internal reflection fluorescence (TIRF) microscopy, the high sensitivity and signal-to-noise
ratio enables the analysis of detailed information of different subcomplexes colocalization
or stoichiometric assembly (Figure 1.4 d-f).
Fluorescence intensity is a direct indicator of single-molecule imaging
measurements. It is associated with either the physical parameters of biocomplexes like
18

Figure 1.4 Single molecule immobilization strategies and analysis.
a. Cell extract prepared from cultured cells before immobilized on pretreated slides. b.
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Representative TIRF image of immobilized cell-derived vesicles with GFP label. e. Dual
color colocalization of biocomplexes with different subunits. f. Single molecule pull down
assay for stoichiometry study. g. Example of photobleaching analysis to achieve
stoichiometry information.
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structure and assembly, or chemical parameters of labeled molecules such as molecular
interactions and the mobility of biomolecules. Single-molecule photobleaching is a
powerful tool to study the stoichiometry of protein complexes as well [127, 128]. A protein
subunit labeled with a fluorescent probe is photobleached by sufficient excitation and gives
a stepwise decrease in fluorescence (Figure 1.4g). By simply counting bleaching steps, the
distribution can assist in quantifying the assembly of protein complexes. For example, in
chapter 3, we use single GFP molecules to label the nAChR subunit and link the
fluorescence to the stoichiometry of the molecular complex. More straightforward, due to
photobleaching of fluorescent tags, the assembly of nAChRs can be statistically quantified
by counting the number of GFP bleaching steps.
1.4.2 TIRF microscopy
During the last several decades, many single-molecule fluorescence microscopy
related techniques have been developed and commercialized, which enable us to exploit
better optical imaging in biological systems. TIRF microscopy is one of the most useful
single-molecule imaging methods. Compared to conventional epifluorescence microscopy,
TIRF microscopy is particularly suitable to study kinetics and dynamics of molecules near
the plasma membrane during cell studies [129]. TIRF can restrict an evanescent field to
less than 100 nm from the coverslip by utilizing totally reflected excitation light then
selectively illuminating events within this region (as shown in Figure 1.5) [130]. Thus,
TIRF delimits the background fluorescence by limiting detection from out-of-focus areas,
enhancing the signal-to-noise ratio, and reducing the photodamage. In the meanwhile, the
development of an electron multiplied charge-coupled device (EMCCD) allows for faster
imaging with low-light fluorescence, expanding the application of TIRF microscopy.
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TIRF microscopy (TIRFM) can be achieved in both prism-based and objectivebased style. Prism-based TIRFM provides better optical confinement, which ensures the
lowest auto-fluorescence and scatters. Objective-based TIRFM is more common because
it can easily switch between epifluorescence and TIRF. Since it could only excite the
fluorophores within the thin evanescent field, TIRFM is an ideal technique to identify and
visualize single fluorescent molecules at or near the cellular membrane. TIRFM has been
successfully employed to monitor cellular processes like endocytosis and cytoskeleton
[131-134]. Combined with single-molecule pull-down assay, TIRFM has also been used to
study the composition, stoichiometry, and conformation of heterogeneous biocomplexes
[126, 135].
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Figure 1.5 Schematic illustration of total internal reflection fluorescence (TIRF)
microscopy.
a, Basic setup of an objective based TIRF microscope. b, top: Epifluorescence. The
excitation beam travels perpendicular to the cover glass, excited all fluorophores. bottom:
TIRF. The excitation beam is completely internally reflected in the glass coverslide at the
surface with the sample. Only fluorescent molecules within an extremely thin axial region
could be exited.
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1.4.3 Confocal microscopy
Confocal microscopy, most frequently confocal laser scanning microscopy
(CLSM), is a point detection-based technique that permits observation of a select layer of
thick samples. Marvin Minsky developed the initial invention of confocal microscopy in
the mid-1950s (patented in 1957) [136]. Then the first application of confocal microscopy
was utilized to visualize unstained brain sections and ganglion cells by David Egger and
Mojmir Patran in 1967 [137]. This microscopy does not increase the resolving power of
the instrument but removes out-of-focus signals from each imaging section by inserting a
small pinhole [138]. In other words, it improves the resolution along the viewing axis and
gives high contrast fluorescence pictures. As shown in Figure 1.6., the excitation light is
focused on sample, and the emission light from the focused plane is passed through a
pinhole into a detector. Fluorescence signals from the out-of-focus region are blocked by
the detection pinhole, which enables the laser to focus down to a single pixel in the
specimen. With the significantly increased signal-to-noise ratio, confocal microscopy can
be utilized in many studies related to protein mechanisms at the single molecule level. For
instance, video-rate confocal microscopy allows scientists to observe the diffusion motion
of cAMP receptors of Dictyostelium discoideum at the surface of COS-7 cells [139].
Besides, recently developed Gallium Arsenide Phosphide (GaAsP) detectors have
significantly increased detection sensitivity compared to traditional photo-multiplier tubes.
The Airyscan confocal microscopy from Zeiss provides excellent axial resolution and
signal-to-noise ratio, which enables, for example, the study of nanoscale pollen
morphology [140, 141]. Confocal microscopy is also the foundation of many new optical
techniques, such as multi-photon microscopy and some of super-resolution microscopy.
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Figure 1.6 Schematic depiction of a typical confocal microscope.
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1.4.4 Multi-photon Microscopy
Multi-photon microscopy is an alternative to confocal microscopy for some
applications such as imaging into thick tissue. Although the description of the first
nonlinear scanning optical microscope was reported in 1978, one has to wait until 1990 to
see the invention of the first real multi-photon microscope [142, 143]. The theoretical basis
behind two-photon microscopy is two-photon excitation, which was described by Maria
Goeppert-Mayer in 1931 [144]. The concept of two-photon excitation (2PE) is that two
low-energy photons were absorbed almost simultaneously (about one femtosecond, 10-15s)
to excite a fluorophore from one energy level to a higher energy level. It equals the energy
required by single-photon excitation, as shown in Figure 1.7a. This process typically
requires a high-power laser with very fast pulses. In a confocal microscope, there is a
pinhole placed in the optical pathway to block the out-of-focus light. In a two-photon
microscope, a laser is focused on a tiny focal plane in the sample, and the emitted
fluorescence is selectively detected without disturbing the out-of-focus light (Figure 1.7 b
right). Since 2PE is a nonlinear process, the intensity of light is high in the center of focus
and falls off quadratically as the distance increases from the focal point of the objective.
As a result, fluorescent molecules away from the tiny focused region do not undergo an
excitation processes, which presents a confocal-like effect.
Two-photon microscopy has several advantages compared to confocal microscopy.
First, the wavelength used in two-photon microscopy is usually in the 700-1,100 nm (nearinfrared) range, which is intrinsically more penetrating than visible light. The scattering
light is also significantly reduced. As a result, two-photon microscopy can image up to
1.6mm deep in tissue [145]. Till now, two-photon microscopy is still the best option for in
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vivo imaging. Second, two-photon excitation significantly decreases the photodamage that
enables continuous imaging in vivo. Calcium imaging of neuronal networks is a good
illustration of the power of two-photon microscopy [146]. Third, there is less waste of
fluorescence signals from samples because of the localization of excitation in two-photon
microscopy. Confocal microscopy places a pinhole to block out-of-focus light, which
causes a significant loss of photons. Currently, two-photon microscopy is involved in many
biomedical studies, from living cells, organs, to brains.
Two-photon excitation has also proven to be a useful tool for single-molecule
imaging since it improves the signal-to-background ratio. An example of this is the study
carried out by Mertz (1995), which demonstrated the two-photon images of single
rhodamine B molecules in solution [147]. Another example of spatial improvement are the
two-photon images of immobilized single rhodamine B molecules, which was presented
by Erik Sanchez (1997) [148]. What stands out in the application of 2PE for singlemolecule studies is the technological growth of fluorescence correlation spectroscopy
(FCS). In 1995, the first two-photon molecular excitation to FCS study in living cells was
reported by Berland et al. [149].
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Figure 1.7 Comparison of one-photon excitation and two-photon excitation.
a. Jablonski energy diagram comparison of single photon excitation (left) and two photon
excitation (right). b. Cartoon illustrating the excitation volume for single-photon and twophoton excitation of fluorescence.

27

1.4.5 Fluorescence correlation spectroscopy
Fluorescence correlation spectroscopy (FCS) is a well-established technique based
on the analysis of the fluctuation of fluorescent signals resulting from fluorescently labeled
molecules that diffuse through confocal detection volume [150-152]. This spectroscopy
was first introduced by Magde et al. in 1972 [153] and then experienced huge growth over
the following years. When using a confocal FCS set-up, a laser is focused into the sample
solution, and fluorescence signals are detected by single photon counting avalanche
photodiodes (APDs). The diffraction limited excitation beam and combined with a micron
sized pinhole offers a tiny detection volume (Figure 1.8a). In a two-photon FCS set-up, the
pinhole can be omitted. Interestingly, one-photon excitation and two-photon excitation
FCS measurements in living cells have been demonstrated to yield identical results through
a comparison by Schwille et al. [154].
FCS relies on the statistical analysis of the fluctuation of fluorescent intensities over
space and time (Figure 1.8b). The autocorrelation function (G(τ)) is applied to measure the
self-similarity of a time signal, which is defined as:
𝐺𝐺 (𝜏𝜏) =

<𝛿𝛿𝛿𝛿(𝑡𝑡)∗𝛿𝛿𝛿𝛿(𝑡𝑡+𝜏𝜏)>
<𝛿𝛿𝛿𝛿(𝑡𝑡)>2

(Eq. 1.1)

Where 𝛿𝛿𝛿𝛿(𝑡𝑡) is defined as a t-dependent deviation of signals from its average over

time, and < > represents the average.

𝛿𝛿𝛿𝛿(𝑡𝑡) = 𝐼𝐼 (𝑡𝑡)−< 𝐼𝐼(𝑡𝑡) >

(Eq. 1.2)

The autocorrelated function can be plotted as shown in Figure 1.8c. It is then fitted
with different mathematical models. Thus, the parameter information of diffusion time (τ),
diffusion coefficient (D), the number of molecules (<N>), and molecular brightness can be
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obtained. FCS measurements could be applied to study molecular interactions, including
the rate of conformational dynamics, binding kinetics and other mobility-related
parameters. For example, both absolute RNA concentration and DNA methylation has been
determined by FCS measurements [155, 156]. Besides, compared to the traditional
nanoparticle characterization technologies, FCS can not only be used to measure the size,
diffusion properties, and absolute concentration of vesicles, but also to evaluate the
conjugation of nanoparticles.
Microfluidic devices are commonly used in biomedical and chemical studies,
which provides advantages such as high sensitivity, small sample volume, and short
detection time. To date, several reports have shown that FCS enables one to measure the
flow profiles and determine flow rates in microfluidic devices with extreme sensitivity
[157-160]. The primary benefit of FCS is the high spatial resolution that results in the
mapping of flow profiles from a small dimension of measurement.

In addition to

microchannels, FCS could also be applied to many different microstructures to determine
flow properties, as well as diffusion-based motions.
Applications of FCS now extended to in vivo studies with many technical advances.
For example, characterizing proteins in the cellular environment is of vital importance to
understand their function. FCS measurements at specific localizations in living cells
provide diffusion and composition changing information of protein complexes [161, 162].
With the development of super-resolution microscopy, which overcomes the resolution
limit, FCS is further exploited to tune the focal volume below the diffraction limit [163,
164]. Thus, the high spatial and temporal resolution of FCS makes it an ideal tool for many
studies across different areas.
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Figure 1.8 Overview of fluorescence correlation spectroscopy (FCS).
a. Representative images of fluorescent molecules moving through detection area (confocal
volume). b. The recording time versus fluctuation of fluorescence intensity trace. c. The
corresponding autocorrelation function calculated from b. It also shows the principle of
calculation of molecular number and diffusion time.
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PROJECT MOTIVATION AND OVERVIEW

Nicotine, one of the most addictive compounds found in cigarette smoke, acts on
nicotinic acetylcholine receptors (nAChRs) and influences the release and inhibition of
many neurotransmitters, including ACh, GABA, dopamine, glutamate and so on. Nicotine
is associated with addiction, increased cognition, many different types of cancer, as well
as cardiovascular and cerebrovascular functions. Understanding nicotine-induced
physiological changes in vivo are essential to identify drug targets for smoking cessation
and many other associated diseases. Advances in single-molecule imaging make it an ideal
tool in examining molecular mechanisms of various biosystems. Thus, the studies
displayed in this dissertation mainly focus on developing novel biophysical approaches to
investigate membrane receptor assembly and physiological changes under the effect of
nicotine.
In the first part of this dissertation study, the assembly of nAChRs in vivo has been
explored, especially in the case of low dose nicotine exposure and withdrawal. The
upregulation of nAChRs is believed to be an essential cause leading to nicotine addiction.
This phenomenon is defined as changes in nAChR expression, trafficking, and
stoichiometry after exposure to nicotine, which leads to modifications in their functions
[86, 165, 166]. The α4β2 subtype is the most abundant nAChR in the CNS and has two
distinct stoichiometries, (α4)2(β2)3 and (α4)3(β2)2. Evidence for nicotine-induced
upregulation of α4β2 nAChRs, as well as the intracellular mechanism including
pharmacological chaperone and intracellular trafficking, are well demonstrated for in vitro
studies. However, these methods are not capable of quantifying the biomolecule assembly
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that takes place in a live animal. Hence, an ideal manner that allows quantifying protein
changes under different physiological conditions is in urgent need.
Previous studies suggest that chronic nicotine exposure in vivo leads to increased
numbers of high sensitivity α4β2 nAChRs, as well as having shown brain region selectivity
when comparing the assembly of α4β2 nAChRs between the cortex and thalamus. These
studies were able to measure relative numbers of α4 and β2 nAChR subunits using western
blots [167]. Another study has shown the relative amount of high-sensitivity (HS) and lowsensitivity (LS) α4β2 receptors in the rat brain by performing electrophysiology
experiments [97]. However, the exact proportion of the two stoichiometries and the
distributions of these two isoforms in across different brain regions remained unclear. Our
lab has quantified the structural assembly of α4β2 nAChRs in cell culture-based systems
using single-molecule techniques in previous publications [83]. Based on these previous
studies, we sought to verify that both α4β2 nAChR subtypes exist in the mouse brain. We
also hypothesized the relative amount of each stoichiometry in the brain that could be
selectively altered by nicotine.
Thus, we developed an approach utilizing nanoscale vesicles extracted from brain
regions combined with single-molecule imaging to monitor how an animal's physiological
condition regulates the dynamics of protein distributions in different brain regions. The
overview of this method is shown in Figure 2.1. This method was used to determine the
effect of nicotine on the distribution of (α4)2(β2)3 and (α4)3(β2)2 nAChRs in several
different mouse brain regions. We demonstrate that both nicotine-induced upregulation and
changes in nAChR stoichiometry differ across brain regions. We found that moderate
levels of upregulation, induced by low dose nicotine, were sufficient to cause significant
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Figure 2.1 Overview of brain region specific single-molecule imaging approach.
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shifts in nAChR stoichiometry in the hippocampus and cortex, but not other brain regions.
This novel single-molecule approach revealed that nicotine acts differentially across brain
regions to alter assembly in response to exposure and withdrawal.
Moreover, we realized that, to better study membrane receptors at single-molecule
level, nanoscale vesicles derived from cells need to be well characterized. Brain-derived
nanoscale vesicles are a type of cell-derived vesicle (CDV). Similar to extracellular
vesicles (EVs), both CDVs and EVs are generated from cellular membranes. Combining
vesicle production with single-molecule fluorescence imaging, CDVs can be utilized to
investigate protein compositions, membrane receptor stoichiometries, and dynamic
changes in protein interactions [96, 126]. More importantly, both CDVs and EVs have been
explored as therapeutic delivery vehicles [168, 169]. Surface proteins on these vesicles are
of great importance as they are characteristic to the cell of origin and modulate vesicle
interactions with target cells.
Thus, in the second part of this dissertation, we developed a high-throughput
fluorescence correlation spectroscopy (ht-FCS) approach to enable characterization of
vesicle surface proteins across a large number of samples. We used automated screening
and acquisition of FCS data to profile surface proteins of cell-derived vesicles with high
fidelity based on changes in diffusion time upon antibody-vesicle interactions. The
overview of the method is shown in Figure 2.2. Utilizing ht-FCs, we characterized vesicles
generated from 4 cell types using antibodies for known exosome biomarkers. The ht-FCS
technique presented here offers the capability to screen EVs or cell-derived vesicles against
a library of surface markers or to screen a library of cell-derived vesicles for a specific
identifying marker at a high speed.
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Figure 2.2 Overview of high-throughput fluorescence correlation spectroscopy (ht-FCS).
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In the third part, this dissertation focuses on developing a new cerebral blood flow
(CBF) measurement method. FCS can not only be applied to characterize the size, diffusion
properties, and concentration of particles, but also to evaluate flow properties. To date,
FCS has been widely used to determine flow rates and flow profiles in microfluidic devices.
However, the application of FCS in animal studies has proven challenging. Here, in chapter
5, we demonstrated a novel application of multi-photon in vivo FCS for the measurement
of CBF with excellent spatial and temporal resolution. This method enables the
quantification of flow rates at each pixel with sub-micron resolution to monitor dynamic
changes. Scanning the excitation beam using FCS provides pixel by pixel mapping of flow
rates with sub-vessel resolution across capillaries 250 µm deep in the brains of mice.
Changes in CBF are attributed to nicotine-induced physiological changes. This
newly developed technique will allow us to monitor blood flow dynamic changes and
quantify the permeability of the blood-brain barrier (BBB) during exposure to nicotine. We
could link BBB disruption with cerebrovascular dysfunction together, which would further
help us to determine the potential mechanisms between vascular functions and nicotine use
disorder. Besides, with the high resolution in vivo images acquired by multi-photon
microscopy, we could further study possible relationships between neurovascular coupling
with dynamic changes of CBF by recording the Ca2+ fluorescence signals from neurons
and astrocytes with the same time scale of blood flow velocity measurements.
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Figure 2.3 Overview of in vivo FCS for blood flow measurements.
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BRAIN REGION SPECIFIC SINGLE-MOLECULE FLUORESCENCE
IMAGING
This chapter is reproduced with permission from [Fu, X., Moonschi, F.H., Fox-Loe, A.M.,
Snell, A.A., Hopkins, D.M., Avelar, A.J., Henderson, B.J., Pauly, J.R., and Richards, C.I.,
Brain region specific single-molecule fluorescence imaging. Analytical Chemistry, 2019,
91, 10125-10131.] Copyright © 2019 American Chemical Society
3.1

Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs), the target of nicotine's

rewarding and reinforcing effects, functionally assemble as pentamers composed of alpha
(α2-10) and beta (β2-4) subunits. Chronic exposure to nicotine increases the expression
level of some nAChR subtypes and influences their trafficking. Nicotine also alters the
assembly of α4β2 nAChRs, the predominate subtype in the central nervous system,
resulting in a shift in their stoichiometry. The two stoichiometries, (α4)2(β2)3 and
(α4)3(β2)2, exhibit distinct pharmacological properties [30]. Nicotine induced upregulation
and changes in receptor stoichiometry are believed to play a critical role in several
processes related to nicotine addiction [78, 86, 166]. However, the long-term changes in
the structural assembly of nAChRs during nicotine exposure and withdrawal are not fully
understood.
While nicotine-induced upregulation has been demonstrated both through in vitro
and in vivo studies [86, 88, 170, 171], quantitative measurements of changes in the
stoichiometry of α4β2 nAChRs have been restricted to in vitro studies in cells [96, 126,
172]. Studies using heterologous expression in isolated cellular systems provide insight
into receptor assembly, but they lack the context of the complex environment present in an
animal. This is particularly true in the central nervous system (CNS) where neuronal and
glial interactions shape processes ranging from protein expression to cellular function and
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communication [173]. Thus, observations in vitro may not correspond to that of native
protein in vivo.
Single-molecule imaging techniques enable the study of complex biological
dynamics, including molecular structure, protein interactions, and functional activity [174,
175]. One of the primary advantages of single-molecule imaging is the elimination of
ensemble averaging seen with traditional techniques, thus providing detailed information
of population distributions and dynamic interactions. This provides a way to delineate
protein populations that exhibit different conformational states, functional states, and
assemble into multiple stoichiometries [176, 177]. Single-molecule imaging has been
extensively applied to purified proteins providing new insights into protein-protein
interactions, conformational changes, complex assembly, and functional activity of a wide
variety of biomolecules [178, 179]. Outside of single-molecule measurements, studies of
changes in receptor stoichiometry have been limited to indirect methods that are not
capable of quantifying changes in population distributions between different α4β2 nAChRs
assemblies. Despite inherent challenges such as fluorophore labeling, sensitivity, and
complex biological environments, single-molecule studies are now regularly used to study
protein dynamics in cells in culture [180-182]. Recent technological advances such as
single-molecule pull-down (SiMPull) along with other techniques have also helped extend
quantitative studies of protein stoichiometry, interactions, and activity to a wider array of
biomolecules [121, 183].
However, single-molecule techniques have not been routinely used to study the
regulation of protein dynamics using whole animal approaches. Complex tissue
architecture, cell heterogeneity, low light penetration, and lack of imaging sensitivity
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makes the extension of single-molecule techniques in vivo more challenging than
previously encountered in transitioning single-molecule studies to live cell imaging. The
ideal technique would quantify proteins of biological processes within an animal at specific
time intervals with single-molecule resolution. Nicotine has been shown to act
differentially across areas of the brain leading to varying levels of upregulation in different
brain regions such as the mid-brain, cortex, and hippocampus. Nicotine also acts in a cellspecific fashion inducing upregulation to a higher degree in GABA neurons compared to
dopaminergic cell bodies [184, 185].
Here we developed a technique that uses the rapid extraction of nAChRs trapped in
nanoscale vesicles composed of their original cellular membrane within the brain. Vesicles
are generated either from a whole brain preparation or specific microdissected mouse brain
regions. Brain region specific vesicles are produced by fractioning cell membranes from
isolated target regions. Receptors remain in their endogenous membrane, thus maintaining
their structural integrity. We utilized this approach to study the assembly profile of the
α4β2 nAChRs extracted directly from animals at specific time points.

3.2

Methods

3.2.1 Experimental section
Animal Care. The α4-GFP knock-in mouse strain was acquired from Dr. Jerry
Stitzel's Lab (Institute for Behavioral Genetics University of Colorado) and maintained in
Dr. James Pauly's Lab (University of Kentucky, Department of Pharmaceutical Science).
The study used male mice that were 2-5 months old at study initiation. All experiments
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were conducted within the guidelines set forth by the National Institutes of Health and were
approved by the University of Kentucky's Institutional Animal Care and Use Committee.
Nicotine treatment. Chronic nicotine was administrated using implanted osmotic
pumps (model 1002, Alzet) at a dosage of 0.7 mg/kg/hr (free base) for 12 days. Sterile
saline was filled in osmotic pumps as a control. For all surgeries, mice were anesthetized
by isoflurane and pumps were implanted subcutaneously. After 12 days of treatment,
nicotine administration was stopped by removing the osmotic pumps. Some animals were
euthanized immediately following pump removal and others were housed for another 7 and
21 days for nicotine withdrawal studies.
Vesicle isolation. Mice were euthanized with Fatal-Plus (Vortech) followed by
cardiac perfusion with 1x PBS. Fresh mouse brain tissue was obtained and kept in cold
homogenization buffer (0.32M sucrose, 10mM HEPES, pH 7.4, 2mM EDTA, and protease
inhibitor). For whole brain single molecule imaging studies, the entire brain tissue was
used to produce α4β2 nAChRs containing vesicles. For brain region specific single
molecule imaging study, the regions of interest were initially separated using a 2mm mouse
brain matrix (Zivic) followed by additional microdissection. The same brain regions from
3 to 5 mice were combined together to generate nanovesicles. Fresh brain tissue was
homogenized immediately using a dounce homogenizer (PYREX) with 2 mL cold
homogenization buffer. 3 mL of additional buffer was added to this mixture and
centrifuged at 200xg for 15 min to remove large tissue. The supernatant of brain lysate was
centrifuged at 1,000xg for 15 min at 4 oC to remove the pelleted nuclear fraction. Then, the
supernatant was collected and subjected to ultra-centrifugation at 10,000xg for 20 minutes
at 4 oC to remove mitochondria. The supernatant was again centrifuged at 100,000xg for 2
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hours at 4 oC. This yielded a pellet containing vesicles which was resuspended in 1x PBS
buffer and aliquots were stored at -80 oC until use.
TIRF Imaging. Before imaging, samples were immobilized on clean functionalized
glass bottom dishes. A glass bottom dish was cleaned by sonicating in 5 M NaOH solution
for 1 hour and then in 0.1 M HCl solution for 1 hour at 45 oC. After rinsing with water and
ethanol 3 times each, the cleaned dish was dried by compressed air and cleaned by oxygen
plasma (Harrick Plasma PDC-32G). To functionalize the dish, 1mg/mL Saline-PEG-Biotin
in 95% ethanol, 0.1 mg/mL NeutrAvidin in 1x PBS, and 1μg/mL biotinylated anti-GFP
antibody in 1x PBS were treated to the dish for 30 minutes sequentially. Between each step,
the dish was rinsed 3 times with 1x PBS. Before binding vesicles, empty cleaned
functionalized glass bottom dishes were imaged to confirm the absence of background in
each dish.

Finally, single vesicles were spatially isolated and immobilized on this

functionalized dish by incubating at room temperature for 30 minutes. The dish was again
rinsed with 1x PBS 3 times to remove unbound vesicles. Immobilized vesicles were
maintained in 1mL 1x PBS during imaging.
Brain derived nanovesicles were imaged using total internal reflection fluorescence
(TIRF) microscopy. TIRF imaging is a powerful technique that reduces background
fluorescence but increases resolution by focusing on a single, optical plane. Only
fluorescent molecules within 100-200nm of the glass surface could be efficiently excited.
A 488nm DPSS laser (~60 W/cm2) was used to excite green fluorescent protein (GFP). The
beam traveled through the appropriate dichroic and filter to the objective (1.49NA, 60x oil
immersion) wherein the angle was adjusted to gain total internal reflection (TIR) using a
stepper motor. The emission light was detected by an electron multiplying charge coupled

42

device (EMCCD) (Andor). An auto focus module (Olympus ZDC2) was used to diminish
focal drift. A TIFF stack containing 800 to 1000 continuous frames with 100 ms exposure
time was acquired for each field of view.
Confocal Imaging. Similarly, mice were treated with nicotine (0.7 mg/kg/hr) or
saline using osmotic pumps (model 1002, Alzet). Following drug administration, mice
were euthanized with Fetal Plus and subjected to cardiac perfusion with 1xPBS. The brain
was then quickly removed and frozen using isopentane in dry ice and then stored at -80 oC.
Later, Brains were sectioned at 20 μm using a cryostat (Lecia CM1850). Brain slices were
mounted with Vectashield (Vector labs, H-1000) in the day of imaging. A Nikon A1Rsi
laser scanning confocal microscope equipped with a 20X 0.9NA Plan Apo water objective
was used for confocal imaging. 20X images were collected by using 5x5 large imaging
combination.
Receptor Autoradiography. To corroborate the single molecule findings,
quantitative receptor autoradiography was used to measure α4β2 nAChRs in a subset of
animals. Following animal euthanasia, the brains were immediately removed and frozen
in isopentane that was chilled in dry ice. Brains were sliced using a Lecia CM1850 cryostat
to make a series of 16-micron thick sections. Receptor density was assessed using [3H]Epibatidine autoradiography (100 pM incubation concentration) and previously established
methods. RayMax Beta High Performance Autoradiography Film was used to visualize the
areas of ligand binding following a 3-day exposure. All films were processed using Kodak
D-19 developer and binding data were analyzed using NIH imageJ and expressed as
uncalibrated optical density in arbitrary units.
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Dynamic Light Scattering. Brain nanovesicle preparation is the same as described
above. All samples for DLS measurement were filtered by a standard syringe filter (0.45µm)
A ZetaPALS potential Analyzer (Brookhaven Instruments) was used to collect the DLS
measurements of vesicle size.
Western Blot Analysis. Western blots were used to determine α4-GFP isolation
from brain lysate. Denatured whole brain nanovesicle fraction were loaded into a prepackaged NuPAGE 4-12% Bis-Tris gel (Life Technologies). Bands were transferred to a
nitrocellulose membrane after electrophoresis. The membrane was first blocked at room
temperature for 1 hour with a PBST solution (5% non-fat milk, 0.1% Tween in PBS). AntiGFP antibody was then added in a 1:1000 dilution and incubated overnight at 4 oC. The
following day, primary antibody was removed by rinsing the membrane with PBST
solution 4 times 5-minute incubation. Secondary anti-rabbit antibody (Jakson
ImmunoResearch) was added to the membrane in a 1:5000 dilution and incubated for 1
hour at room temperature. Secondary antibody was removed in the same way by rinsing
the membrane with PBST solution 4 times 5-minute incubation. After removal of PBST
solution from the membrane, bands were visualized by chemiluminescent detection
(Clarity, Bio-Rad) using Chemi-Doc system (Bio-Rad).
Photobleaching Step Analysis. Customized Matlab scripts were written to generate
time traces from image sequences and analyze photobleaching steps. Briefly, the first 10
frames of the TIFF stack were combined to a composite image, which was employed to
find peaks by comparing with the user defined threshold value. A 3-pixel x 3-pixel region
of interest (ROI) was selected at each peak position to read the intensity and a 5-pixel x 5pixel region around peak was used to measure the background. The background was
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subtracted from the intensity of each ROI. Changes in the intensity occurring at each peak
over the length of this stack, a time trace, was determined and saved as a text file. This file
was then used to plot the time trace and count the number of photobleaching steps. Finally,
results from different TIFF stacks were accumulated to generate a distribution of
photobleaching steps.
Photobleaching steps were determined manually according to the stepwise decrease
of fluorescence decay. A single molecule was accepted with the following criteria: (1) the
time trace of a single molecule should have at least one clear bleaching step (but on more
than 3 steps); (2) the GFP molecule fluorescence (each bleaching step) had to last at least
10 frames (1 s); (3) the mean intensity needed to be 3 times higher than the standard
deviation of the mean count of the background. All data sets were analyzed blindly at least
twice, and the results were only accepted after comparison of results from each analysis
round.
3.2.2 Statistical Analysis
The actual distribution of bleaching steps was calculated by fitting the observed
distribution to a binomial distribution. The probability of the observed k number of
photobleaching steps, for a receptor with n number of labeled subunits is calculated as
following:
𝐹𝐹(𝑘𝑘, 𝑛𝑛, 𝑝𝑝) =

𝑛𝑛!

𝑘𝑘!(𝑛𝑛−𝑘𝑘)!

𝑝𝑝𝑘𝑘 (1 − 𝑝𝑝)𝑛𝑛−𝑘𝑘

(Eq. 3.1)

Where, p is the probability of GFP being observed. Here, the probability of GFP in
a fluorescence state was determined as 0.85. For (α4)2(β2)3 receptor in our study, two
stoichiometries ((α4)2(β2)3 and (α4)3(β2)2) lead to different probabilities of 1, 2, and 3
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photobleaching steps. Modeling the probability of k number of photobleaching steps for
(α4)2(β2)3 receptors requires a combination of two binomial distributions (Eq. 3.2).
𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,𝑘𝑘 = 𝑎𝑎𝑘𝑘 ∗ 𝐹𝐹1 (𝑘𝑘, 2, 0.85) + 𝑎𝑎𝑘𝑘′ ∗ 𝐹𝐹2 (𝑘𝑘, 3, 0.85)

(Eq. 3.2)

Where, F1 and F2 corresponds to the case when 2 and 3 GFP labeled α4 subunits
are in the receptor respectively. 𝑎𝑎𝑘𝑘 and 𝑎𝑎𝑘𝑘′ are the fractions used to weight the distributions

to obtain the stoichiometry. The observed 1 bleaching step from either (α4)2(β2)3 and

(α4)3(β2)2 could be expressed as:
𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,1 = 𝑎𝑎1 ∗ 𝐹𝐹1 (1, 2, 0.85) + 𝑎𝑎1′ ∗ 𝐹𝐹2 (1, 3, 0.85)

(Eq. 3.3)

𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,2 = 𝑎𝑎2 ∗ 𝐹𝐹1 (2, 2, 0.85) + 𝑎𝑎2′ ∗ 𝐹𝐹2 (2, 3, 0.85)

(Eq. 3.4)

Similar to the observed 2 bleaching steps:

The observed 3 bleaching steps could only come from (α4)3(β2)2:
𝐹𝐹𝑡𝑡𝑡𝑡𝑡𝑡,3 = 0 + 𝑎𝑎3′ ∗ 𝐹𝐹2 (3, 3, 0.85)

(Eq. 3.5)

Therefore, the probability of (α4)2(β2)3 after fitting is 𝑎𝑎1 + 𝑎𝑎2 , and 𝑎𝑎1′ + 𝑎𝑎2′ + 𝑎𝑎3′ is

the probability of (α4)3(β2)2. Once the data was fit to a binomial, the weighted distribution

of the two stoichiometries was summarized in a simple graph. Error bars on the observed
data represent the square root of counted number of observed events. Error bars on fitted
distributions represent 95% confidence intervals. Statistical significance (α=0.05) was
determined between groups using a 2-proportion Z test.
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3.3

Results and Discussions

3.3.1 Chronic, low dose nicotine induces modest but significant levels of nAChR
upregulation
The action of nicotine on nAChRs is believed to be an essential part of the
mechanism of addiction [170, 186]. The α4β2 nAChR is the predominant subtype
expressed in the CNS and has been shown to have a critical role in nicotine reward,
dependence, and withdrawal [49, 84, 187]. Chronic administration of nicotine increases the
density of neuronal nAChRs in vivo. To examine this phenomenon, we first measured
binding of [3H]epibatidine in different brain regions for both nicotine and saline treated α4GFP Knock-In (KI) mice. The density of neuronal nAChRs was visualized and measured
by nearly saturated [3H]epibatidine binding sites. As shown in Figure 3.1a and b, at the low
dose of chronic nicotine administration (0.7 mg/kg/hr via osmotic minipump), we observed
clear upregulation in the cortex (~10%) and the hippocampus (dentate gyrus
temporoammonic path and medial perforant path) (~25%) compared to the saline treated
group (See Table S3.1).
To specifically examine nicotine induced up-regulation of α4* nAChRs, we
performed confocal microscopy of 20 micron brain slices to image the fluorescence
intensity of the GFP signal. Two confocal images of the representative cortical and
hippocampus brain slice section from α4-GFP KI mice are shown in Figure 3.1c and d.
Higher fluorescence intensity in the hippocampus was observed in the mice exposed to
nicotine (0.7mg/kg/hr), which agrees with the radioligand binding studies. Verifying that
chronic nicotine administration upregulates α4* nAChRs in the α4-GFP KI mice used for
single molecule studies.
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Figure 3.1 Upregulations of nAChRs.
a and b, Representative autoradiographic comparison of [3H]-Epibatidine binding from
brains of the α4-GFP knock-in mice pretreated with nicotine (0.7 mg/kg/hr) and saline,
respectively, showing upregulation in the hippocampus. c and d, Representative confocal
imaging comparison from brains of the α4-GFP knock-in mice pretreated with nicotine
(0.7 mg/kg/hr) and saline. Arrows indicate upregulation in the hippocampus.
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These experiments confirm that chronic, low dose nicotine only moderately
increased the high affinity binding of [3H]epibatidine and the expression level of nAChRs.
This agrees with previous in vivo studies showing that upregulation scales with the amount
of nicotine delivered. These studies also verify the selectivity of nicotine induced
upregulation in vivo across different brain regions, with the greatest increase in nAChR
expression in the hippocampus.
3.3.2 Generation and characterization of the α4* brain nanovesicles
To determine correlations between upregulation and receptor stoichiometry, we
performed single molecule experiments to examine the changes in receptor assembly in
response to the animal's physiological condition. Here, we developed a novel technique to
perform brain region specific single molecule analysis via the rapid extraction of receptors
isolated in nanovesicles. The receptor isolation strategy for the entire mouse brain and
specific brain regions is shown in Figure 3.2. Nanoscale vesicles are generated directly
from brain tissue obtained from α4-GFP KI mice. These vesicles encapsulate single
receptors within the physiological membrane where they resided at the time of extraction.
A total internal reflection fluorescence microscopy (TIRFM) image of isolated vesicles
containing α4β2 nAChRs is shown in Figure 3.3a. To further characterize brain derived
nanovesicles, we employed dynamic light scattering (DLS) to determine the size of vesicles
in our preparations. Vesicles range in size from 90 to 150 nm in diameter (Figure 3.3b).
The size of vesicles is small enough that they spatially isolate nAChRs at the single
molecule level. The isolation of GFP containing receptors in vesicles was verified via
western blot using an anti-GFP antibody (Figure 3.3c).
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In order to determine the assembly of α4β2 nAChRs, we recorded the fluorescence
intensity versus time traces for each single vesicle to show a stepwise decay of fluorescence
(Figure 3.3d and e). Photobleaching steps within each time trace correspond to the number
of GFP labeled subunits. Since nAChRs assemble as pentamers, the observed distribution
of bleaching steps arises from the combination of (α4)2(β2)3 and (α4)3(β2)2 stochiometries.
The observed population distributions were fit to binomial distributions to extract the ratio
of the two stoichiometries (see Methods Section and supplementary figures).
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Figure 3.2 Isolation of α4β2 nAChR containing nanovesicles from mouse brain tissue.
Schematic depicting the generation of brain-derived nanovesicles containing single α4β2
nAChR. The whole brain (top) from α4-GFP KI mice is homogenized to form small
fragment of brain tissues. The resulting lysate is purified to acquire nanoscale vesicles
which maintain single α4β2 nAChRs in the same physiological membrane they resided in
prior to extraction from the brain. The vesicles are sorted from the cell debris resulting in
isolated nanoscale vesicles. Individual brain regions (bottom), such as the cerebellum and
hippocampus, are dissected and then separated to generate region specific nanovesicles.
Vesicles are prepared from brain regions specific tissue in the same fashion as described
for whole brain.
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Figure 3.3 Characterization of brain α4β2 nAChR nanovesicles.
a, A representative image of isolated vesicles containing α4β2 nAChRs. b, Size distribution
from DLS measurement of brain derived nanovesicles. c, Western blot verifying the
isolation of α4-GFP from brain preparations. d, Time traces of photobleaching steps from
isolated single vesicles showing 2 bleaching steps caused from two GFP molecules which
suggest a (α4)2(β2)3 stoichiometry in theory. Similarly, three photobleaching steps e
corresponds to a (α4)3(β2)2 stoichiometry.
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3.3.3 Stoichiometric distribution α4β2 nAChRs in whole brain preparations
Cell culture based single molecule experiments have tied upregulation of nAChRs
to changes in stoichiometry [96]. However, the native population distribution of each
stoichiometry and changes in this distribution upon exposure to nicotine within the brain
is still unknown. In order to correlate in vivo upregulation with changes in receptor
stoichiometry, we utilized our single molecule approach examine the regulation of α4β2
nAChR expression in native brain tissue.
We first determined the baseline distribution of the two populations of α4β2 nAChR
stoichiometries. We then evaluated the effect of chronic nicotine treatment on receptor
assembly in the entire mouse brain. In the saline treated group, the distribution of observed
photobleaching steps were fit to binomial distributions weighted to 48% of (α4)2(β2)3 and
52% of (α4)3(β2)2. This matches previous in vitro reports that suggest an equal ratio of the
two α4β2 nAChR stoichiometries [188]. After 12 days of chronic nicotine exposure (0.7
mg/kg/hr), the α4β2 nAChRs exhibited a distribution of (α4)2(β2)3 and (α4)3(β2)2 of 55%
and 45%, respectively which was significantly different than the saline group (α=0.05)
(Figure 3.4). The result of the whole brain studies gives a slightly higher fraction of the
(α4)2(β2)3 stoichiometry than observed in cells, which is in agreement with the existence
of low numbers of various subtypes of neuronal α4 containing nAChRs, such as α4α5β2,
α4α6β2 [189, 190].
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Figure 3.4 Distributions of α4β2 nAChR assembly whole brain preparations.
a. Schematic illustration of the generation of whole brain-derived nanovesicles containing
single α4β2 nAChR. Observed (blue) and fitted (red/black) distributions of one, two, or
three bleaching steps for the α4β2 nAChRs encapsulated in brain derived nanovesicles
from the saline treated group b, and the nicotine treated group c. Error bars are the square
root of the number of vesicles counted. These expected distributions fit a binomial of 48%
of (α4)2(β2)3 and 52% (α4)3(β2)2 in the saline group and 55% of (α4)2(β2)3 and 45%
(α4)3(β2)2 in the nicotine group d with statistical significance between saline and nicotine
conditions. Error bars are 95% confidence intervals. A 2 proportion Z test was used to
determine significance at α=0.05
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3.3.4 Brain region specific stoichiometric distribution of α4β2 nAChRs
We then determined the population distribution of α4β2 nAChR stoichiometries
across different brain regions. These brain region specific single molecule studies were
used to determine whether the selectivity of nicotine-induced upregulation in different
brain regions correlates with changes in the distribution of receptor stoichiometries. We
separated and performed nanovesicle extraction from the cerebellum, cortex, hippocampus,
hypothalamus, midbrain, striatum, and thalamus (Figure 3.5). Receptors encapsulated in
both cortex and hippocampus derived nanovesicles showed that, in the absence of nicotine,
the distribution of α4β2 nAChRs fit a binomial weighted for 41% (α4)2(β2)3 and 59%
(α4)3(β2)2. A clear nicotine-induced shift in stoichiometry was observed in these two
regions with 12 days of chronic nicotine treatment (0.7mg/kg/hr). In the presence of
nicotine, single-molecule analysis of isolated α4β2 nAChRs derived from the cortex
showed the majority of receptors assemble as the high sensitivity stoichiometry of
(α4)2(β2)3, weighted to 60% of (α4)2(β2)3 and 40% of (α4)3(β2)2. Similarly, vesicles
generated from the hippocampus were fitted to 61% of (α4)2(β2)3 and 39% of (α4)3(β2)2
(Figure 3.5b). Distributions of observed photobleaching events and their fitting results are
shown in supporting information (see Supplementary Figure S3.1 and S3.2). While we
observed statistically significant shifts in stoichiometry in the hippocampus and cortes,
α4β2 nAChRs encapsulated in nanovesicles originating from the remaining five brain
regions, cerebellum, hypothalamus, midbrain, striatum, and thalamus, showed no
statistically significant shifts due to chronic nicotine treatment. Two stoichiometries of
α4β2 nAChRs weighted to similar, near equivalent proportions of (α4)2(β2)3 and (α4)3(β2)2
subtypes in all five brain regions with or without nicotine exposure (Figure 3.5c).
55

Distributions of observed photobleaching events and their fitting results are shown in
supporting figures (see Supplementary Figure S3.3-S3.7). The absence of a shift for α4β2
nAChR expression in these regions could provide a new explanation of selectivity in
nicotine induced upregulation in the brain.
Comparing the distribution of low sensitivity and high sensitivity α4β2 nAChRs
between whole brain preparations and previous cell based studies [96, 172], we found a
higher fraction of high sensitivity stoichiometry receptors in the whole brain preparations.
This further emphasizes the need for single molecule stoichiometry studies from animals
as the homogeneous cell culture environment lacks the complexity present in vivo. Here
low levels of nicotine exposure led to undetectable changes in receptor stoichiometry in
the cerebellum, hypothalamus, midbrain, thalamus, and striatum. Higher levels of nicotine
exposure have routinely been shown to lead to upregulation in variety of studies [71, 191].
However, upregulation has not previously been correlated to in vivo changes in
stoichiometry. This new single molecule approach was used to observe robust changes in
α4β2 nAChR assembly in the cortex and the hippocampus even at these moderate levels of
upregulation. It suggests that structural changes in receptor assembly are more sensitive
and responsive to nicotine than other commonly observed physiological changes such as
nAChR upregulation. Thus, even low levels of nicotine appear to have significant
consequences.
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Figure 3.5 Nicotine treatment caused stoichiometric changes of α4β2 nAChRs in different
brain regions.
a. Schematic illustration of the generation of brain region specific nanovesicles containing
single α4β2 nAChR.

b. The fitted populations of the 2 possible α4β2 nAChR

stoichiometries from the hippocampus and the cortex in saline (left) and nicotine (right). c.
The distribution of stoichiometries in brain regions showing no changes when animals are
exposed to nicotine (right) as compared to saline (left). Error bars are 95% confidence
intervals. There was a significant difference at α=0.05 for the cortex and hippocampus
regions between saline and nicotine treated groups using a 2 proportion Z test.
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3.3.5 Changes in α4β2 nAChR stoichiometric distribution during withdrawal
To capture changes in receptor stoichiometry that occur during nicotine withdrawal,
we also utilized our method to examine the stoichiometry of α4β2 nAChRs for time points
after exposure to nicotine. We compared animals with no nicotine, at 12 days of nicotine
exposure, and after withdrawal from nicotine at time points of 1 and 3 weeks (Figure 3.6).
Single-molecule bleaching event analysis was applied to study the stoichiometric assembly
of α4β2 nAChRs captured in brain regions specific vesicles. The distributions of α4β2
nAChRs in 5 different brain regions, in the presence of nicotine, were analyzed (Figure
3.6b, left). Single-molecule analysis of photobleaching events from nanovesicles extracted
from the cortex after day 7 of withdrawal showed 44% (α4)2(β2)3 and 56% (α4)3(β2)2.
After a 21-day nicotine withdrawal, nanovesicles encapsulating single α4β2 nAChRs from
the cortex were distributed as 42% (α4)2(β2)3 and 58% (α4)3(β2)2, which represented the
same stoichiometric distribution as the control group (Figure 3.6b and Figure S3.8).
Analysis of hippocampus associated receptors showed a distribution of 49% (α4)2(β2)3
and 51% (α4)3(β2)2 at 7-day withdrawal, and 41% (α4)2(β2)3 and 59% (α4)3(β2)2 at 21-day
withdrawal (Figure 3.6b and Figure S3.9). However, single α4β2 nAChRs isolated from
the cerebellum, midbrain, and thalamus, exhibited no significant differences in their
assembly in the presence of nicotine or after nicotine withdrawal (Figure 3.6b and
Supplementary Figure S3.10-S3.12). This demonstrated that nicotine induced upregulation
of α4β2 nAChRs was brain region specific and that stoichiometry returns to the original
population distribution after withdrawal.
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Figure 3.6 Nicotine withdrawal caused stoichiometric changes of α4β2 nAChRs in
different brain regions.
a. Schematic illustrating the nicotine withdrawal study. b. The population distribution of
the two possible stoichiometries of α4β2 in five different brain regions with nicotine
treatment (left), 7-day withdrawal (middle), and 21-day withdrawal. Nicotine altered the
stoichiometry of receptors in the cortex and hippocampus but not in the other regions. The
cortex fully returned to baseline distributions after 7 days of withdrawal while the
hippocampus returned to baseline levels after 3 weeks of withdrawal. The remaining brain
regions showed no change in distribution during nicotine administration or after
withdrawal. Error bars are 95% confidence intervals. There are significant differences
(α=0.05) for the cortex and hippocampus regions between nicotine treated and 1-week
withdrawal groups. There is also a significant difference for the hippocampus between 1week withdrawal and 3-week withdrawal groups using a 2-proportion Z test.
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These studies reveal a reversal of the upregulation and demonstrate that our single
molecule approach is capable of following the time course of changes in protein
populations taking place within live animals. The longer period of withdrawal that was
observed for the hippocampus to return to baseline stoichiometry also further suggests
differential effects of nicotine across brain regions.

3.4

Conclusion
We have developed a new technique that allows us to perform single molecule

measurements of proteins synthesized and modified in the CNS of an animal. This
technique relies on the generation of nanoscale vesicles from microdissected brain regions.
Vesicles are composed of the identical membrane where the receptors resided immediately
prior to formation. This maintains the vesicles in an environment that supports their
structural integrity but still provides spatial isolation for single molecule imaging. We
utilized this novel method to determine the proportion of (α4)2(β2)3 and (α4)3(β2)2 nAChR
stoichiometries in native brain tissue. Our approach takes snap shots in time of the receptor
population at multiple time points during modifications to receptor assembly that occurred
during nicotine exposure and withdrawal.
In these studies, we confirm that low dose nicotine induced upregulation is
associated with stoichiometric changes and it has high selectivity within different regions
of the brain (Figure 3.7). Our novel technique, provides insight into how an animal's
physiological environment alters assembly of nAChRs in the brain. For the first time, we
observed single molecule changes in receptor assembly that occurred with a live animal.
These studies provide a general method to use quantitative single molecule measurements
of biomolecular processes occurring in an animal. The observation of robust stoichiometry
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changes in response to low levels of nicotine with only modest upregulation points to a
prominent role for nAChR structural changes in nicotine addiction and provides further
evidence of the differential behavior between brain regions in response to nicotine.
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Figure 3.7 Schematic depicting chronic nicotine treatment induced dynamics in population
distributions of α4β2 nAChR stoichiometries in different brain regions.

62

Supplementary information

Figure S3.1 Binomial distributions showing nicotine increases (α4)2(β2)3 in the cortex.
Observed (blue) and fitted (red/black) distributions of one, two, or three bleaching steps
for the α4β2 receptors encapsulated in cortical vesicles from the saline treated group a, and
the nicotine treated group b. Error bars are the square root of the number of vesicles
counted. These expected distributions fit a binomial of 41% of (α4)2(β2)3 and 59%
(α4)3(β2)2 in the saline group and 60% of (α4)2(β2)3 and 40% (α4)3(β2)2 in the nicotine
group c.
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Figure S3.2 Binomial distributions showing nicotine increases (α4)2(β2)3 in the
hippocampus.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the hippocampus in the saline treated group a, and the nicotine
treated group b. Error bars are the square root of the number of vesicles counted. The saline
treated group fits a distribution of 41% (α4)2(β2)3 and 59% (α4)3(β2)2. The nicotine treated
group fits a distribution of 61% (α4)2(β2)3 and 39% (α4)3(β2)2 c.
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Figure S3.3 Distributions of the α4β2 receptor assembly in the cerebellum with and without
the presence of nicotine.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the cerebellum in the saline treated group a, and the nicotine treated
group b. Error bars are the square root of the number of vesicles counted. Both saline
treated group and nicotine treated group fit a distribution of 45% (α4)2(β2)3 and 55%
(α4)3(β2)2 c.
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Figure S3.4 Distributions of the α4β2 receptor assembly in the hypothalamus with and
without the presence of nicotine.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the hypothalamus in the saline treated group a, and the nicotine
treated group b. Error bars are the square root of the number of vesicles counted. The saline
treated group fits a distribution of 50% (α4)2(β2)3 and 50% (α4)3(β2)2. The nicotine treated
group fits a distribution of 42% (α4)2(β2)3 and 58% (α4)3(β2)2 c.
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Figure S3.5 Distributions of the α4β2 receptor assembly in the midbrain with and without
the presence of nicotine.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the midbrain in the saline treated group a, and the nicotine treated
group b. Error bars are the square root of the number of vesicles counted. The saline treated
group fits a distribution of 51% (α4)2(β2)3 and 49% (α4)3(β2)2. The nicotine treated group
fits a distribution of 52% (α4)2(β2)3 and 48% (α4)3(β2)2 c.
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Figure S3.6 Distributions of the α4β2 receptor assembly in the striatum with and without
the presence of nicotine.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the striatum in the saline treated group a, and the nicotine treated
group b. Error bars are the square root of the number of vesicles counted. Both saline
treated group and nicotine treated group fit a distribution of 56% (α4)2(β2)3 and 44%
(α4)3(β2)2 c.
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Figure S3.7 Distributions of the α4β2 receptor assembly in the thalamus with and without
the presence of nicotine.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the midbrain in the saline treated group a, and the nicotine treated
group b. Error bars are the square root of the number of vesicles counted. The saline treated
group fits a distribution of 50% (α4)2(β2)3 and 50% (α4)3(β2)2. The nicotine treated group
fits a distribution of 52% (α4)2(β2)3 and 48% (α4)3(β2)2 c.
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Figure S3.8 Binomial distributions of the α4β2 receptor stoichiometry showing the effect
of nicotine withdrawal in the cortex at time points of 1, and 3 weeks.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the cortex in the 1-week nicotine withdrawal group a, and the 3weeks nicotine withdrawal group b. Error bars are the square root of the number of vesicles
counted. The expected distribution fits to 44% (α4)2(β2)3 and 56% (α4)3(β2)2 in the 1-week
withdrawal group. The 3-weeks withdrawal group fits to 42% (α4)2(β2)3 and 58%
(α4)3(β2)2 c.
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Figure S3.9 Binomial distributions of the α4β2 receptor stoichiometry showing the effect
of nicotine withdrawal in the hippocampus at time points of 1, and 3 weeks.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the hippocampus in the 1-week nicotine withdrawal group a, and
the 3-weeks nicotine withdrawal group b. Error bars are the square root of the number of
vesicles counted. The expected distribution fits to 49% (α4)2(β2)3 and 51% (α4)3(β2)2 in
the 1-week withdrawal group. The 3-weeks withdrawal group fits to 41% (α4)2(β2)3 and
59% (α4)3(β2)2 c.
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Figure S3.10 Binomial distributions of the α4β2 receptor stoichiometry showing the effect
of nicotine withdrawal in the cerebellum at time points of 1, and 3 weeks.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the cerebellum in the 1-week nicotine withdrawal group a, and the
3-weeks nicotine withdrawal group b. Error bars are the square root of the number of
vesicles counted. The expected distribution fits to 40% (α4)2(β2)3 and 60% (α4)3(β2)2 in
the 1-week withdrawal group. The 3-weeks withdrawal group fits to 45% (α4)2(β2)3 and
55% (α4)3(β2)2 c.
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Figure S3.11 Binomial distributions of the α4β2 receptor stoichiometry showing the effect
of nicotine withdrawal in the midbrain at time points of 1, and 3 weeks.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the midbrain in the 1-week nicotine withdrawal group a, and the 3weeks nicotine withdrawal group b. Error bars are the square root of the number of vesicles
counted. The expected distribution fits to 50% (α4)2(β2)3 and 50% (α4)3(β2)2 in the 1-week
withdrawal group. The 3-weeks withdrawal group fits to 52% (α4)2(β2)3 and 48%
(α4)3(β2)2 c.
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Figure S3.12 Binomial distributions of the α4β2 receptor stoichiometry showing the effect
of nicotine withdrawal in the thalamus at time points of 1, and 3 weeks.
Observed and expected distributions of one, two, or three bleaching steps for the α4β2
receptors isolated from the thalamus in the 1-week nicotine withdrawal group a, and the 3weeks nicotine withdrawal group b. Error bars are the square root of the number of vesicles
counted. The expected distribution fits to 50% (α4)2(β2)3 and 50% (α4)3(β2)2 in the 1-week
withdrawal group. The 3-weeks withdrawal group fits to 47% (α4)2(β2)3 and 53%
(α4)3(β2)2 c.
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Table S3.1 The relative autoradiographic binding intensity of [3H]-Epibatidine binding
from brains of the α4-GFP knock-in mice pretreated with nicotine (0.7mg/kg/h) and saline.
Saline

Nicotine

Parietal cortex (layers 5, 6)

91.60 ± 2.82

99.20 ± 3.01

Parietal cortex (layers 1-4)

56.36 ± 1.81

64.99 ± 3.16

Dentate Gyrus
Temporoammonic Path

55.87 ± 0.86

73.69 ± 4.64

Dentate Gyrus Media
Perforant Path

56.53 ± 1.34

76.15 ± 3.01

Medial Habenula

184.98 ± 1.41

187.18 ± 1.89

Striatum

117.04 ± 4.01

122.56 ± 4.28
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HIGH-THROUGHPUT FLUORESCENCE CORRELATION
SPECTROSCOPY ENABLES ANALYSIS OF SURFACE COMPONENTS OF
CELL-DERIVED VESICLES
This chapter is reproduced with permission from [Fu, X., Song, Y., Masud, A., Nuti, K.,
DeRouchey, J.E., and Richards, C.I., High-throughput fluorescence correlation
spectroscopy enables analysis of surface components of cell-derived vesicles. Analytical
and Bioanalytical Chemistry, 2020, 412(11): 2589-2597.] Copyright © 2020 SpringVerlag GmbH Germany, part of Spring Nature

4.1

Introduction
In the last chapter, we have utilized brain-derived nanoscale vesicles to investigate

membrane receptor assembly. The brain-derived vesicles are also a type of cell-derived
vesicle that maintain the integrity of receptors from the membranes of its physiological cell
of origin. Cell plasma membrane (PM), consisting of both lipids and proteins, is of central
importance for maintaining cell physiology. It is often challenging to study detailed
molecular changes between the cell membrane and its original environment, such as
endocytosis and exocytosis, ion conductions, cell division, nutrients and viral uptake [192].
Remodeling membrane systems provides a feasible way for investigating the lipid-lipid,
lipid-protein, protein-protein interactions. While synthetic vesicles, like pure lipid vesicles
(liposomes), lack the compositional integrity of the cellular PM. One such new membrane
model system are the cell-derived vesicles (CDVs), which are artificially generated from
the membranes of organelles within the cell. Similar to extracellular vesicles, these vesicles
show more native-like properties. CDVs now are widely used to investigate PM
composition, physical properties, protein transporters, and ion channel conductions [192195].
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Extracellular vesicles (EVs) secreted by cells into the extracellular domain, serve
as natural nanoscale delivery systems for biological systems to transport cargo (e.g. lipids,
proteins, RNA) between cells. For example, these endogenous vesicles have been
implicated in cancer progression and metastasis by transferring bioactive molecules [196,
197]. EVs also play a role in cell-cell communication by initiating signaling cascades in
target cells [198]. Because of these traits, endogenous vesicles along with synthetic vesicles
(liposomes and cell-derived vesicles) are being harnessed for the development of new
therapeutic delivery vehicles [169, 199]. Both natural and artificial vesicles composed of
cellular membranes have proven to be stable, biocompatible, and able to deliver a wide
range of therapeutic cargo [169, 200, 201]. One of the primary barriers to identifying and
characterizing EVs is that they often exist in complex heterogeneous mixtures derived from
a variety of cell types. While many surface proteins are similar across most EVs and cellderived vesicles (CDVs), others are characteristic for vesicles derived from specific cell
types [202-204]. These membrane proteins are believed to provide EVs and CDVs with
the capability to recognize recipient target cells from the diverse and heterogeneous
mixture of EVs and cell types within a biological system [205]. Characterizing unique
surface proteins could be used as a method to screen and identify EV and CDV populations
[206].
CDVs have shown similar properties (size, targeting, surface proteins) to those seen
for EVs [169, 207-209]. Current analysis methods to identify vesicle surface proteins are
low throughput and struggle to distinguish heterogeneities that could be used to assign the
cell of origin. Identification of the composition of surface proteins of EVs and CDVs would
provide the capability to identify different vesicle species. Existing technologies utilized
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for vesicles characterization include e flow cytometry [210], western blotting [211], and
mass spectrometry [212]. Each of these methodologies suffer from limitations in measuring
heterogenous mixtures of vesicles including low sensitivity, low throughput, and averaging
over the entire population of vesicles. A comparison of these techniques for EV studies is
shown in Supplementary table S4.1.
Fluorescence correlation spectroscopy (FCS) is a well-established technique based
on the analysis of the fluctuation of fluorescent signals resulting from the diffusion of
labeled molecules moving through a confocal detection volume [150-152]. These
fluctuations can be used to determine the number, molecular brightness, and diffusion
coefficient of fluorescently labeled biomolecules. Additionally, FCS measurements can be
applied to study the dynamics of molecular interactions between biomolecules. Therefore,
FCS can be used to not only measure the size, diffusion properties, and absolute
concentration of vesicles, but also evaluate the binding of specific antibodies to vesicles
[213]. This provides the capability to identify the number of specific exosome populations
within a heterogeneous mixture by FCS.
FCS measurements, however, are traditionally based on a manual workflow of data
acquisition leading to relatively low throughput analysis due to samples needing to be
replaced after each acquisition. Recently, high throughput FCS approach has been used to
monitor the diffusion of biomolecules in different subcellular regions [162, 214]. Our
studies extend high throughput FCS for the characterization of vesicles and for use as a
high throughput screening assay. Here, we utilize a high-throughput screening FCS (htFCS) approach that allows automatic screening of numerous samples within in a well plate
(e.g. 96 wells). This allowed for rapid characterization of vesicle surface components and
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was used to assign vesicle cellular identity. CDVs were generated from a series of different
cell lines and screened against exosome marker antibodies to identify surface protein
species. We developed software and hardware platforms to scan multiple wells
automatically allowing us to screen several antibodies against each vesicle type. The
combination of high-throughput screening and FCS enables fast acquisition times, analysis
of the size distribution of cell-derived vesicles from different cell sources, the identification
of the cell of origin, and the relative level of surface protein expression.

4.2

Methods
Cell culture. Human lung cancer (A549) cells, human embryonic kidney 293

(HEK293) cells, neuroblastoma 2a (N2A) cells and macrophage-like (RAW264.7) cells
were purchased from American Type Culture Collection (ATCC) and cultured using
standard tissue culture techniques. A549 cells and HEK293 cells were grown in growth
media consisting of Dulbecco's Modified Eagle Medium (DMEM), supplemented with
10% fetal bovine serum (FBS), 1% penicillin/streptomycin. N2A cells were cultured in
DMEM

and

Opti-MEM

growth

media

supplied

with

10%

FBS

and

1%

penicillin/streptomycin. RAW 264.7 cells were cultured in Roswell Park Memorial
Institute

(RPMI)

1640

medium

supplemented

with

10%

FBS

and

1%

penicillin/streptomycin. DMEM, Opti-MEM, RPMI, FBS, and penicillin/streptomycin
were purchased from VWR (Pennsylvania, USA). All types of cells were maintained in
atmosphere of 5% CO2 in a humidified incubator at 37oC. Cells were passaged after
reaching 90% confluence, detached with cell scraper to generate vesicles.
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Vesicle isolation. We generated vesicles through nitrogen cavitation [126, 215].
Cells were scraped from T75 flasks in 5mL sucrose buffer solution (250 mM sucrose, 10
mM HEPES, pH 7.5, and protease inhibitors (Roche)). All of the cell slurry was collected
and centrifuged at 200xg for 5 min to pellet the cells. The cell pellet was resuspended in 5
mL sucrose-HEPES buffer. Then vesicles were generated using nitrogen cavitation with a
pressure of 250 psi for 5 minutes. Cell lysate was collected and centrifuged at 4,000xg at
4 oC for 10 minutes to remove the pelleted nuclear fraction. Supernatant was collected and
centrifuged at 10,000xg for 20 minutes at 4 oC. The pellet was discarded, and supernatant
was subjected to ulta-centrifugation at 100,000x g for 1 hour at 4 oC. This yielded a pellet
containing vesicles which was resuspended in 1x PBS buffer and stored at -80 oC until use.
Dynamic Light Scattering. For the DLS measurements, a ZetaPALS Potential
Analyzer (Brookhaven Instruments, Holtsville, NY) with a 658 nm (29 mW) helium-neon
laser was used to determine average hydrodynamic diameters of vesicles from different
cell types. Vesicles were prepared as described above and then filtered by a standard
syringe filter (0.45 µm). 1 mL of each sample were measured in triplicate in a plastic
cuvette at 90°. All measurements were carried out at 25 °C. Results are presented as mean
+/- standard deviation.
Vesicle labeling. To fluorescently label vesicles, 5µM DiI was added to the vesicle
resuspension and incubated at 37 oC for 40 minutes. Then vesicles were purified using a
0.45 µm corning sterile syringe filter to remove larger debris. The vesicles were further
purified by using a 5000 molecular weight cutoff size exclusion column (PD Minitrap G25,
GE Healthcare) to remove spare free dye.
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To determine vesicle surface components, 5 different antibodies were- used- antiCD9 antibody, anti-CD63 antibody, anti-CD81 antibody, anti-Hsp70 antibody, and antiAlix antibody (BioLegand). Each was labeled with CF543 dye using antibody labeling kits
(Mix-n-Stain, Biotium) before being added to the vesicle resuspension. The antibody
labeling protocol followed manufacturer instructions. Vesicle samples from the same type
of cell were mixed and filtered with a 0.45 µm syringe filter. The filtered sample was then
aliquoted. 0.5 µg/mL CF543 labeled antibody was added to each aliquoted sample and then
incubated for 1 hour at room temperature. Vesicles were purified by using size exclusion
column as described in the previous section.
Western Blot Analysis. Vesicle surface components were verified by western
blotting analysis. Denatured vesicle resuspensions were loaded into a pre-packaged
NuPAGE 4-12% Bis-Tris gel (Life Technologies). Bands were transferred to a
nitrocellulose membrane after electrophoresis. The membrane was then blocked for 1 hour
and incubated overnight with selected primary antibody at 4 oC. We used the following
antibodies (in 1:1000 dilution): anti-CD9 (cat. 312102), anti-CD63 (cat. 353018), antiCD81 (cat. 349502), anti-HSP70 (cat. 818101), anti-Alix (cat. 634502). All antibodies
were from BioLegend, San Diego, CA. After rinsing and removal of the primary antibody,
secondary antibody was added and incubated for 1 hour at room temperature. Then, the
membranes were washed again, and bands were visualized by chemiluminescent detection
(Clarity, Bio-Rad) using Chemi-Doc system (Bio-Rad).
Fluorescence correlation spectroscopy. FCS measurements were performed on a
home-built microscope. Approximately, 40µl fresh prepared fluorescently labeled sample
was placed onto a coverslip mounted on an Olympus IX83 microscope equipped with a
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PicoQuant PicoHarp 300 Time-Correlated Single Photon Counting (TCSPC) system. We
employed a 532nm laser (45 µW) to excite the fluorescent labels and a 60x water
immersion objective was used to focus this laser beam in the sample solution. Two
avalanche photodiodes (APDs) were used for photon detection connected to a PicoHarp
300 TCSPC module controller. All FCS results are an average of at least 3 measurements,
with sampling times of 40 s. To diminish the background signal from immobilized
molecules, we performed all measurements 30µm above the glass surface in the sample
solution.
For high-throughput screening application, a customized program was written to
generate automatic continuous scanning of the system. A script was written in C++ using
Visual Studio 2015 that controlled all hardware (e.g. prior motorized stage and Picoharp
300)

within

the

system.

The

script

can

https://bitbucket.org/ywsong2/uky_ptu_convert/src/master/.

be
The

accessed
system

can

at
be

programmed with an input configuration file to move the stage in specific increments and
patterns, to correlate stage dwell time in each well and photon time trace data collection
(Picoharp 300) and collect and store photon arrival times for each data trace. This allowed
automation of the FCS data collection across the entire well plate. For measurements, a
glass bottom 96-well plate with fresh prepared samples (40µl each well) is loaded to the
microscope. The motorized prior stage is initialized and moves based on the user defined
configuration. An automatic immersion water supply device is equipped to replace the
evaporating volume from the objective. All acquisitions of HT-FCS data were packed and
processed to the SymPhoTime 64 (PicoQuant) for analysis.
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Analysis of Fluorescence Correlation Spectroscopy. All data analysis was
performed through SymPhoTime 64. After recording the fluctuations of the time versus
fluorescence intensity trace, which recorded the diffusing fluorescent species in the
detection volume, the autocorrelation function is applied and defined as following:
𝐺𝐺 (𝜏𝜏) =

<𝛿𝛿𝛿𝛿(𝑡𝑡)∗𝛿𝛿𝛿𝛿(𝑡𝑡+𝜏𝜏)>
<𝛿𝛿𝛿𝛿(𝑡𝑡)>2

(Eq. 1.1)

Where I(t) represent the intensity time trace with a unit of Hz. The brackets denote
averaging over time. The autocorrelation data were further fitted with a triplet kinetics
model (eq. 2) comprising one or two components:
𝐺𝐺 (𝑡𝑡) = [1 + 𝑇𝑇 �exp �−
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(Eq. 4.2)

Where 𝜏𝜏𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 is the diffusion time of the ith diffusing species in ms, and 𝜏𝜏 𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 is the

lifetime of the dark (triplet) state. 𝑛𝑛𝐷𝐷𝐷𝐷𝐷𝐷𝐷𝐷 represents number of independently diffusing
species. ρ stands for the contribution of the ith diffusing species. κ is the length of diameter

ratio of the focal volume. This fitting model allows us to extract the diffusion time and
number of molecules (concentration) from FCS curves.
At the start of each acquisition, we used commercial 0.1µm tetraspeck beads
(Invitrogen) to calibrate the FCS focal volume by serial dilution of a known concentration
of beads (1.8 x 1011 particles/mL) combined with counting the number of molecules in the
focal volume.
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4.3

Results and Discussions

4.3.1 Verification of FCS for vesicle size measurements
Binding of fluorescently labeled ligands to larger biomolecules can be monitored
via FCS [216]. The diffusion time scales with the hydrodynamic radius and can be
calculated from the autocorrelation of a fluorescence time trace of molecules freely
diffusing in solution. As a ligand binds to a larger biomolecule, a characteristic shift is
observed in the measured diffusion time. We compared diffusion times for unconjugated
fluorophores, fluorescently labelled antibodies, and immunolabeled vesicles. As shown in
the 30 sec segment of a fluorescence time traces in Figure 4.1, characteristic bursts in
fluorescence intensity were observed which correspond to fluorescent molecules diffusing
into the laser focal volume. The height of a burst, measured in photon counts, depends on
the intensity of the fluorophore and the residence time inside the detection volume. From
these fluorescence intensity time traces, auto-correlation functions (ACF) were used to
evaluate the diffusion times and the number of molecules in solution. The normalized ACF
G(τ) of free dye, labeled antibody, and vesicle bound antibody are shown in Figure 4.1d.
For the unconjugated fluorophore, the fitted ACF yields a diffusion time (τD) of 0.21 ± 0.02
ms. A longer diffusion time of 1.1 ± 0.1 ms was observed for the CF-543 labeled AntiCD63 antibody. The immunolabeled (anti-CD63-CF543 antibody) vesicles (A549)
exhibited a diffusion time of 23 ± 2 ms. The clear shift of diffusion time from these three
ACFs illustrates that we can use FCS to distinguish between antibodies freely diffusing
and those bound to the surface of a vesicle.
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Figure 4.1 Demonstration of the ability of FCS to measure fluorescent molecules over a
different size range.
The recorded fluorescence fluctuations over time from immunofluorescently labeled A549
cell-derived vesicles (a), fluorescent antibody (b), and unconjugated dye(c). d is the
corresponding measured normalized ACF curves from a, b, and c.
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4.3.2 Size distribution of cell-derived vesicles with different origins
Vesicles derived from different types of cells often have different diameters, carry
different cargo, and have differences in surface protein expression. We performed dynamic
light scattering (DLS) analysis of four types of CDVs to determine their hydrodynamic
diameters and then compared them to the diffusion time observed from FCS. Vesicles
derived from cell lines, A549 (lung cancer cells), HEK293T (embryonic kidney cells), N2A
(neuroblastoma cells), and Raw264.7 (macrophage-like cells), were generated by nitrogen
cavitation and purified from cellular debris through several steps of centrifugation. DLS
was used to measure the size distribution of each type of CDVs. We identified vesicles
derived from A549, HEK293T, N2A, and Raw264.7 cells with diameters of 259.5, 269.4,
199.6, and 196.1 nm, as shown in Figure 4.2. The DLS analysis clearly shows a difference
in the size distributions across cell type used to generate the vesicles. Vesicles derived from
HEK293T cells exhibited the largest diameter while those generated from Raw 264.7 cells
had the smallest average diameter.
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Figure 4.2 DLS results show size variance in different CDVs.
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We next used FCS as a comparison measurement of relative vesicle size based on
the observed diffusion time. We used the lipophilic fluorophore DiI to densely label the
vesicle membrane. We recorded fluorescence intensity time traces and fit the resulting
ACFs for vesicles derived from A549, HEK293, N2A, and Raw 264.7 cells which yielded
diffusion times (τD) of 31 ± 2 ms, 38 ± 1 ms, 29 ± 2 ms, 19 ± 4 ms, respectively (Figure
4.3 and Table 4.1). This shift and the magnitude of the observed diffusion times agree with
the DLS measurements we performed.
In addition to diffusion time, the average number of molecules within the focal
volume can also be extracted. The FCS focal volume was calibrated using commercial
0.1µm tetraspeck beads with a known diffusion constant. This allowed us to determine the
concentration of vesicles in solution. Based on the original dilution and the number of
molecules in the focal volume we determined that 20 million A549 cells yielded ~0.7 x
1011 vesicles per mL (0.5mL), 20 million HEK293 cells yielded ~1.3 x 1011 vesicles per
mL (0.5mL), 20 million N2A cells yielded of ~1.4 x 1011 vesicles per mL, and 20 million
RAW 264.7 cells generated 0.5 mL of ~1.1 x 1011 vesicles per mL.
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Figure 4.3 FCS results show size variance in different CDVs.
Normalized autocorrelation functions measured by FCS show a shift of diffusion time.

Table 4.1 DLS and FCS results showing the size of cell-derived vesicles
Cell type

Mean vesicle diameter (nm)

Diffusion time (ms)

A549

259.5 ± 9.2

31 ± 1.9

HEK293T

269.4 ± 6.8

38 ± 1.1

N2A

199.6 ± 4.7

29 ± 1.8

RAW264.7

196.1 ± 6.0

19 ± 3.5
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4.3.3 Establishing the high-throughput FCS measurements
To establish the ht-FCS workflow, we designed and extended a custom FCS
capable confocal microscope to enable automatic screening and data collection of multiple
wells (Figure 4.4). Two laser pathways were aligned to provide pulsed laser and continuous
wave (CW) laser as excitation sources. Laser light is directed through an objective to the
sample and emitted fluorescence light is collected through the same objective and directed
to two avalanche photodiodes (APD) after it passed through the confocal pinhole. The
output from the APDs were directed to a TCSPC module (PicoHarp 300). The experimental
workflow of high-throughput screening is shown in Figure 4.5. The custom designed
program consisted of different modalities to perform programmed stage movements, time
trace collection, and data storage. Each well of the plate were sequentially exposed to 532
nm CW laser excitation during data acquisition for a duration of 40 sec. Each collected
time trace was assigned a unique identifier based on the well location in the plate for each
sample.
Having developed the pipeline for ht-FCS, we next demonstrated the utility of this
technique by screening surface protein compositions of CDVs. Based on the exosome-like
properties of cell derived vesicles, we screened for the presence of 5 established exosomal
markers, including three transmembrane proteins from the tetraspanin family (CD9, CD63,
and CD81), heat shock protein (HSP70), and cytosolic protein (Alix). These proteins are
well-known in HEK cells, N2A cells, A549 cells and Raw 264.7 cell released exosomes.
Antibodies for these surface proteins were labeled with the fluorescent dye CF-543. All
antibodies were measured independently before being added to vesicles. The measured
diffusion times from different antibodies gives similar results. Vesicle samples were
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Figure 4.4 Schematic representation of the ht-FCS experiment setup.
The alignment of ht-FCS is based on a confocal microscopy and modified to fit several
excitation sources. The single photon counter and high throughput screening devices are
mounted on the instrument.
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Figure 4.5 The customized program workflow for high throughput screening process.
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aliquoted and immunolabeled with 500ng/ml for each fluorescently labeled antibody. A
5000 molecular weight cutoff size exclusion column was applied to purify the label vesicles
from residual unconjugated fluorophores.
FCS autocorrelation curves from HEK cell-derived vesicles in response to each of
the panel of antibodies are shown in figure 4.6a. The amplitude of the autocorrelation
function (G(τ)) is inversely proportional to the number of molecules in the detection
volume. The decays are determined by molecular size and diffusion rate. Thus, the variance
in diffusion time and average molecular number shown in Figure 4.6a provides evidence
of the capacity of FCS to detect the immunobinding of surface protein. The longer the
diffusion time the better the binding efficiency of antibodies to vesicles. The exosomal
markers from tetraspanin protein family, anti-CD 9 and anti-CD 63, exhibited similar
binding level to vesicle surface components, whereas the expression level of CD 81 and
cytosolic protein (Alix) were much lower. Interestingly, in contrast to exosomes shed by
HEK 293 cells, there is totally inefficient binding of anti-HSP70 antibody to vesicles.
To further quantify binding efficiency, the number of bound antibodies each vesicle
was determined by calculating the mean fluorescence intensity burst height of free
antibodies (see Figure 4.6b and Figure S4.1) and then comparing to the value for antibody
labeled vesicles. The height of fluorescence bursts scales linearly with the number of
antibodies bound to the vesicles. Figure 4.6b shows a histogram of the number of
antibodies observed for each fluorescence intensity burst during the data acquisition for
four antibodies with HEK vesicles. These data demonstrate the ability to detect surface
proteins present on vesicles and to determine the relative copy number of the surface
proteins.
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Figure 4.6 ht-FCS studies of immunofluorescently labelled CDVs from HEK293T cells.
a. the experimental and fitted autocorrelation functions clearly show a difference in the
diffusion time and thus show the expression level of different proteins in the vesicle
surface. b, Histogram of the calculated number of bound antibodies per HEK cell derived
vesicles.
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We validate these results by western blot analysis, which agree with the FCS studies
showing that HEK cell-derived vesicles express tetraspanin proteins and cytosolic protein
(Alix) but not HSP70. We further verified the presence of the selected proteins (CD9, CD
63, CD81, HSP70, and Alix) in the different vesicle population. CDVs from A549 cells
were responsive to anti-CD9, anti-CD63, and anti-Alix antibodies, but not anti-CD 81 and
anti-HSP70 antibodies. CDVs from N2A and Raw264.7 cells showed no response to antitetraspanin and heat shock antibodies. They only responded to anti-alix antibodies. The
western blots show the presence of the same surface proteins for each vesicle as determined
via FCS (Figure 4.7a).
Lastly, we generated a graphical color-coded table to represent the variant
responses between cell-derived vesicles and exosomal marker antibodies as determined by
ht-FCS. A table containing the details is shown in the supplementary material (Table S4.2).
The yield expression profile and protein abundance in vesicle membrane were based on the
assumption that all antibodies have similar binding affinities to membrane proteins. The
calculated diffusion coefficient, average number of bound antibodies per vesicle, and
diffusion time are shown in Figure 4.7b. Lung cancer cells (A549 cells) derived vesicles
were enriched with CD9 and CD63 proteins but not CD81 and HSP 70. Vesicles from both
N2A cells and Raw264.7 cells did not respond to anti-tetraspanin protein antibodies or heat
shock protein antibodies. In addition, antibody against Alix protein presented a limited
binding capacity to most types of vesicles except Raw 264.7 cell-derived vesicles. In
general, therefore, it seemed that CDVs showed notable difference in membrane protein
expression on their surface with exosomes from the same origin.
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Figure 4.7 ht-FCS studies of immunofluorescently labelled CDVs from different cell lines.
a, Validation of selected exosomal marker proteins by immunoblotting. b, Color table of
antibody binding analysis among 4 different cell-derived vesicles.
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4.4

Conclusion
We developed a high throughput method to screen for vesicle surface proteins using

high-throughput FCS technique. This approach enables the fast and accurate
characterization of surface protein profiles. The combination of high throughput screening
and FCS diminished the limitation of most traditional techniques and provided more
detailed information to characterize vesicles. This approach can be used to identify vesicles
based on surface proteins and to identify the number of each surface protein on the vesicle.
Identification of surface components on vesicles can be used to characterize vesicles and
potentially to identify the cell of origin.
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Supplementary information

Figure S4.1 Calculated mean fluorescence intensity of different free antibodies anti-CD9CF543 antibody
a, Average fluorescence intensity from anti-CD9-CF543 antibody. b, anti-CD63-CF543
antibody. c, anti-CD81-CF543 antibody. d, anti-HSP70-CF543 antibody e, anti-AlixCF543 antibody.
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Table S4.1 The comparison of different methods used in the studies of vesicle
characterization.
FEATURE

HT-FCS

FLOW
CYTOMETRY

WESTERN
BLOT

MASS
SPECTROSCOPY

WHAT IS
MEASURED

Fluorescence
fluctuations

Enhanced
forward scatter

Immunoblotti
ng

Mass-to-charge
ratio of ions

PARTICLE SIZE

Yes

Yes

No

No

CONCENTRATIO
N

Yes

Absolute
number

Relative
concentration

No

PROTEIN
COMPOSITION

Yes (with
surface
marker)

Yes (with
surface marker)

Yes

Yes

Yes

Yes

No

No

SINGLE
PARTICLE
DETECTION

Table S4.2 Antibody binding analysis among 4 different cell-derived vesicles.
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MULTIPHOTON FLUORESCENCE CORRELATION
SPECTROSCOPY FOR QUANTITATIVE, HIGH-RESOLUTION BLOOD FLOW
MEASUREMENTS

5.1

Introduction
In the last chapter, we have used FCS to characterize cell-derived vesicles and

measure the surface binding properties. FCS is a solution-based technique that is
traditionally used to measure the diffusion, surface binding, and concentration of molecules
in vitro [217-221]. FCS has also been exploited to measure flow velocities in microfluidic
devices with high sensitivity [157-160]. FCS depends on the detection of photons from
molecules moving through a defined detection volume, and the subsequent correlation of
the photon time trace yields a signature of fluorescence fluctuations related to molecules
moving in and out of the focal volume [222]. The size and shape of the focal volume
depends on the optical set-up, including the excitation wavelength and intensity, the
numerical aperture of the objective, and the detection pinhole [223]. The microfluidic
device is one of the widely used tools in biomedical and chemical studies to mimic the
large flow systems. It has many advantages, including high sensitivity, small sample
volume, and short detection time. To date, several reports have shown that FCS enables
the measurement of flow profiles and determination of flow rates in microfluidic devices
with extreme sensitivity [157-159].
Cerebral blood flow (CBF) measurements provide critical information about
physiological and pathological processes within the central nervous system (CNS). The
complex microvascular network plays a fundamental role within the CNS, where neuronal
activity regulates the flow of oxygen and nutrients [224, 225]. Understanding blood flow
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dynamics with high spatiotemporal resolution is essential for unraveling the role of
vascular dysfunction in a variety of pathological processes [226, 227]. Ideally, flow rates
could be quantified with sub-capillary resolution providing the capability to map flow rate
cross sections within individual vessels in order to distinguish between flow within the
center vessel compared to that in the vicinity of the wall of the vessel.
Existing methods for blood flow measurements using multi-photon laser-scanning
microscopy (MPLSM) provide the capability to measure changes over time by utilizing
high concentrations of fluorescent dyes in order to visualize vessels and produce a contrast
with red blood cells (RBCs) [227-229]. However, multi-photon blood flow measurements
have not achieved the same spatial and temporal resolution available for multi-photon
imaging [230, 231]. This is in part because they are limited by the scan rate of the
microscope and the requirement to track RBCs over a segment of the vessel, rather than
providing a pixel-level readout of the flow rate [227, 232].
Recently, with the advances in imaging, FCS has been extensively utilized in in
vivo studies to provide diffusion and composition changing information of protein
complexes at specific localization in living cells [161, 162, 233]. Two-photon excitation
has also opened new probabilities in the applications of FCS [160, 234, 235]. Here, we aim
to overcome the limitations of current methods for blood flow measurements in vivo by
combining multi-photon excitation with FCS to demonstrate high spatiotemporal
resolution measurements of blood flow rates in the CNS of live animals. This approach
provides a high sensitivity method with the capability to quantify flow rates with pixel by
pixel mapping across vessels while using only nanomolar concentrations of fluorescent
molecules. We applied this in vivo multi-photon FCS approach to mapping flow velocities
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across vessel sections at a sub-vessel resolution, where the flow rate and concentration of
molecules can be measured in a single pixel (defined by the diffraction limited focal
volume) and without the need for scanning.

5.2

Methods
Animal Care. All experiments were conducted within the guidelines set forth by

the National Institutes of Health (NIH) and were approved by the Institutional Animal Care
and Use Committee (IACUC) at the University of Kentucky. The study used both female
and male mice (C57BL/6) that were 3-6 months old. Mice were housed in cages in group
of three or four animals before surgery and maintained with standard housing conditions
until use.
Animal Preparation. All surgical procedures were conducted in a custom-made
stereotaxic apparatus with temperature controlled (homeothermic pad). Briefly, mice were
deeply anesthetized with isoflurane (3% for induction, 2.0% to 2.5% for surgery) and
subjected to head-bar surgeries. After anesthesia induction, toe-pinch nociceptive reflex
responses were tested. To obtain optical access, we created an open or non-open cranial
window on both sides of mouse hemisphere (approximately 1 mm posterior and 1 mm
lateral from bregma). In the preparation of the thin-skull window, the scalp was removed,
and the surface of the skull, around 5 mm diameter circular area, was polished with a dental
drilling tool until the bone reached transparent to see vasculature. We applied GenTeal
lubricant eye gel to cover the thinned skull surface to keep moisture. After the thin-skull
surgery, the mouse was directly moved to microscope stage to continue the in vivo imaging.
In the open skull cranial window surgery, the scalp was removed, and the surface of the
skull was gently scraped to increase adherence of the head holder. The cranial window was
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filled with saline after a 3 mm diameter skull bone was lifted, and a 5 mm circular
coverglass (#1 thickness) was covered and secured with cyanoacrylate glue (Loctite 416).
We then spread the glue over the skull up to the edge of the skin and cemented a 3D printed
head holder to the skull using dental cement for head fixation during imaging. After the
craniotomy surgery, the mouse was returned to its home cage and allowed to recover for
several days before imaging sessions.
Multi-photon FCS set-up. Fluorescence correlation spectroscopy was performed
with a commercial upright confocal microscope (LSM 880 laser scanning microscope, Carl
Zeiss, Germany), equipped with an InSight X3 wavelength tunable (680 to 1300 nm)
infrared laser. Imaging and FCS recordings were carried out with a long working distance
water immersion objective (W Plan-Apochromat 20x/1.0, Carl Zeiss). Fluorescence
emission was directed with a long pass dichroic mirror onto two non descanned GaAsP
detectors mounted to the side of microscope nosepiece and bandpass filters matching the
emission of each fluorophore were mounted in front of the detectors. Zeiss ZEN Black 2.3,
with the advanced FCS module was used for recording the images and the time correlated
single photon counting (TCSPC) data for the FCS measurements. The same software was
used for analyzing and fitting the FCS data.
Microfluidic chamber flow measurements. A microfluidic chamber was used to
determine the appropriate fluorescence dye and to calibrate the focal diameter of the system.
Briefly, a syringe pump was connected by a tube to a glass coverslip covered microchannel
(Ibidi, Germany) to control the flow rate [160]. The flow volume was set to a series of
values ranging from 0.3 mL/min to 1.5 mL/min. The dimensions (0.1 x 5 x 48.2 mm) of
the chamber are shown in the Figure 1. After these initial measurements, we tested several
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fluorophores for multiphoton FCS measurements. All fluorescent probes were dissolved in
MilliQ water and diluted to a concentration that yielded approximately 5 molecules in the
focal volume. We compared the brightness and stability of all the fluorescent dyes. Of the
brightest fluorophores, we selected two fluorescent dyes with well separated 2-photon
excitation wavelengths to minimize crosstalk during signal collection. The excitation
wavelength of the vessel labeling dye (high concentration dye) was selected for its shorter
excitation wavelength and FCS indicator dye (low concentration dye) for its longer
excitation wavelength. CF488-dextran 250 kDa was chosen as the FCS dye (920 nm
excitation) and Rhodamine B-dextran 500 kDa as the vessel labeling dye (820 nm
excitation). CF 488 and Rhodamine B were selected or in vivo measurements. CF488
Dextran 250 kDa was purchased from Biotium, and Rhodamine B Dextran 500 kDa was
purchased from Nanocs. To diminish bias and accurately calibrate the system, a short
acquisition time with multiple repetitions (e.g., 10 reps x 10 s) was used in the presence
and absence of flow. Averaging of short acquisitions can help recognize the extraordinary
events such as inadvertent spikes due to dust or other anomalies such as breathing artifacts
and these can then be excluded from the final data analysis [236].
In vivo imaging sessions. During imaging sessions, mice were anesthetized with
isoflurane (1.3% to 2.2% in O2) and the body temperature was maintained with an electric
heating pad under the mouse. To visualize the vasculature and measure the flow rate, 100
µL mixture of fluorescent dye (8 µM Rhodamine B Dextran 500 kDa and 300 nM CF488
Dextran 250kDa) was intravenously injected into a ~25 g mouse through either the tail vein
or via retro-orbital injection. The final concentration in the animal was 20 nM for the FCS
tracker and 530 nM for the vascular label. The mouse head needed to be secured and
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stabilized to avoid breathing motion artifacts during the recording of FCS signals. The
effects of breathing artifacts on the photon counting are detailed in Figure 5.10. After
mounting the mouse’s head in a custom-made head restraint under the microscope
objective, we placed GenTeal lubricant eye gel between the window and the objective. The
lubricant has the same index of refraction as water but has the advantage of a much higher
viscosity and limited evaporation during long imaging sessions. Vessels approximately
100-200 µm deep in the neocortical tissue were selected for imaging.
To image the cerebral vasculature, we used the InSight X3 laser set to 820 nm to
excite Rhodamine B. Two-Photon in vivo imaging was conducted to find large vessels and
capillaries. We also performed multiphoton imaging to identify veins and arteries which
were identified by tracing connections and determining whether they were surrounded by
clear continuous lines of smooth muscle. Within the focal plane of a region of interest, we
selected one (single pixel measurement) or several positions (pixel by pixel mapping)
within different vessels. The scanned laser beam was positioned at our selected locations
for the duration of the data collection. CF488 for FCS measurements was excited at 920
nm. Since exogenous fluorescent dyes are quickly cleared from the blood, all flow
measurements were conducted within 60 to 120 min after injection. In order to maintain
signal consistency during the flow measurements, we adjusted the amount of fluorescent
dye injected according to the weight of the mice. The laser power was also adjusted to
maintain a count rate of approximately 50 kHz during the FCS measurements.
To map sub-vessel resolution blood flow velocity, we first positioned the laser
beam in the center of the vessel of interest. Several positions across the entire vessel were
selected in the same focal plane. Then the laser beam was moved sequentially to each
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position, and fluctuations in the fluorescence were collected in each coordinate. Similarly,
to obtain the 2D sectional blood flow velocity profile, we found the center of the vessel
and obtained the fluorescence intensity time trances and then relocated the measurement
point 10 µm up and 10 µm down. For the dynamic flow studies, we slowly increased the
isoflurane rate (from 1.3% to 2.2%) to decrease the animal’s heart rate. Flow velocity was
measured once the heart rate stabilized.
The flow velocity was calculated based on the earlier determined diameter of the
detection volume according to Eq. 5.1.
𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣𝑣 =
5.3

𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟 𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡

(Eq. 5.1)

Results

5.3.1 Calibration of multi-photon FCS set-up in microfluidic devices
We implemented in vivo FCS measurements using an upright multi-photon
microscope with a tunable laser, with an emission spectrum from 680 to 1300 nm. Initially,
we tested several fluorophores for multiphoton FCS measurements (Figure 5.1). We then
performed a series of calibration measurements with known volumetric flow rates and
cross-sectional areas in a microfluidic chamber (Figure 5.2a and b). A representative
photon-counting time trace and its autocorrelation curve for freely diffusing molecules, i.e.
without flow, are shown in Figure 5.2 c and d. After extracting the diffusion parameters in
the absence of flow, we incrementally increased the flow rates, while measuring the
residence time of the molecules within the focal volume. The flow rate dependent residence
time was extracted from the FCS autocorrelation.
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Figure 5.1 Performance of different biosafety dyes in two-photon (2P) fluorescence
correlation spectroscopy (FCS) via microfluidic chambers.
a. Schematic of the microfluidic chamber used to calibrate the optical setup. b-d. The
recorded fluorescence fluctuations over time and their corresponding autocorrelation
curves from CF488-dextran 70 kDa (b), CF568-dextran 10 kDa (c), and Quantum dots 655.
(d). b, Photon counting time traces of CF488-dextran 70 kDa during free diffusion (upper
panel, green), 0.5 mL/min flow rate (middle panel, orange), and 1.5 mL/min flow rate
(lower panel, purple). c, Photon counting time traces of CF568-dextran 10 kDa at free
diffusion (upper panel, light green), 0.5 mL/min flow rate (middle panel, light orange), and
1.5 mL/min flow rate (lower panel, light purple). d, Photon counting time traces of
Quantum dots 655 at free diffusion (upper panel, red), 0.5 mL/min flow rate (middle panel,
blue), and 1.5 mL/min flow rate (lower panel, pink).
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Figure 5.2 Illustration of the calibration of two-photon (2P) fluorescence correlation
spectroscopy (FCS) in microfluidic chamber.
a, Schematic drawing of the multiphoton in vivo FCS setup through a glass slide covered
flow chamber. b, Schematic and dimensions of the microfluidic device. c, Fluorescence
intensity time trace recorded from freely diffusing CF488-Dextran 250 kDa, and d, the
corresponding autocorrelation function (ACF) (G(τ)) reveals the diffusion properties of
CF488-Dextran 250 kDa. e, Normalized ACFs resulting from different rates of flow in the
microfluidic device which was used to calibrate the optical setup. We tested a series of
flow rates (0.4, 0.6, 0.8, and 1.0 mL/min) with CF488-Dextran 250kDa to extract the
residence times. f, Flow velocities with measured flow residence times show linear
relationship, which yields a calculated focal lateral diameter of 0.98 microns for the optical
setup.
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The fluctuations of the fluorescence intensity I(τ) resulting from fluorescent
molecules flowing through the focal volume were analyzed with the temporal
autocorrelation function (Eq. 1.1):
𝐺𝐺 (𝜏𝜏) =

<𝛿𝛿𝛿𝛿(𝑡𝑡)∗𝛿𝛿𝛿𝛿(𝑡𝑡+𝜏𝜏)>

(Eq. 1.1)

<𝛿𝛿𝛿𝛿(𝑡𝑡)>2

The autocorrelation function was then fitted in ZEN Black 2.3 software (Carl Zeiss,
Germany) with following equation (Eq. 5.2):
𝐺𝐺 (τ) =

1
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(Eq. 5.2)

Here, N is the total number of fluorescence particles in the focal volume, 𝑇𝑇𝑡𝑡 is the

triplet fraction, and 𝜏𝜏𝑡𝑡 is the triplet decay time (the lifetime of the dark state). 𝜏𝜏𝑑𝑑 is the

diffusion time and S is the structure parameter which is defined as the ratio between axial
and lateral dimensions of the focal volume. This fitting model allows us to extract the free
diffusion time of pure fluorescence species from FCS curves.
In the presence of flow, the fitting model of the autocorrelation function, G(τ), has
changed to the following form:
𝐺𝐺 (τ) =

1

τ
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(Eq. 5.3)

Here 𝜏𝜏𝑑𝑑 represents the diffusion time of the fluorescent molecules, 𝜏𝜏𝑓𝑓 denotes the

average residence time of the molecule flowing through the focal volume, and N is the
average number of particles in the detection volume. In the case where the diffusion is
much slower than flow rate, (𝜏𝜏𝑑𝑑 ≫ 𝜏𝜏𝑓𝑓 ), the equation simplifies (Eq. 5.4).
𝐺𝐺 (τ) =

1

<𝑁𝑁>

τ

2

exp �− � � �
τ𝑓𝑓
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(Eq. 5.4)

Thus, in the presence of flow, the residence time (𝜏𝜏𝑓𝑓 ) can be extracted by fitting the

autocorrelation function G(τ) to Equation 5.3 and 5.4. The lateral diameter of detection

volume (d) is linked to the velocity (υ) by 𝑑𝑑 = 𝜏𝜏𝑓𝑓 ∗ υ. To calibrate the focal volume of our

system with CF488 dextran 250kDa, we examined a series of flow rates to extract the
residence time. These calculated residence time for a series of volumetric flow rates (flow
volumes of 0.4 to 1.0 mL/min) allowed us to extract the diameter of the focal volume
(Figure 5.1e and f). We observed a diameter of 0.98 microns with a linear relationship
between the residence times and the flow volume. The flow rate was again measured with
a series of fluorophores of different molecular weights to validate the consistency of the
focal diameter and the residence time for a given flow volume.
Traditionally, the FCS focal volume needs to be calibrated with a fluorophore with
a known diffusion coefficient for confocal FCS setup. In our case, we were using 2-photon
excitation and the most important parameters we extracted from our measurements were
the residence time and focal diameter. Thus, we calibrated the optical system with known
volumetric flow rates, flow velocity, and cross-sectional area. We calibrated the optical
system with both CF488-dextran 10 kDa and CF488-dextran 250 kDa. The equatorial
diameter of the focal volume with CF488-dextran 10 kDa and CF488-dextran 250 kDa
were calculated to be 0.87 µm and 0.98 µm, respectively, as shown in Figure 5.3 and Table
5.1 and 5.2.
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Figure 5.3 Validation of two-photon (2P) fluorescence correlation spectroscopy (FCS)
focal volume with different molecular weights of fluorophores .
a. Schematic of FCS focal volume. b and c. Results of CF488-dextran 10 kDa and CF488dextran 250 kDa normalized autocorrelations from bulk flow rates ranging from 0.1
mL/min to 1.0 mL/min.
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Table 5.1 Calibration of the focal volume through CF488-dextran 10 kDa
Flow rate
(ml/min)

Area
(mm2)

Velocity
(mm/s)

Residence time
(µs)

Lateral Diameter
(µm)

0.1

0.5

3.33

265.6

0.885

0.2

0.5

6.67

131.3

0.875

0.3

0.5

10

87.4

0.874

0.4

0.5

13.33

63.8

0.851

0.5

0.5

16.67

52.9

0.881

0.6

0.5

20.00

43.0

0.860

0.7

0.5

23.33

36.3

0.846

0.8

0.5

26.67

32.0

0.854

0.9

0.5

30.00

29.0

0.871

1.0

0.5

33.33

26.0

0.867

Table 5.2 Calibration of the focal volume through CF488-dextran 250 kDa
Flow rate
(ml/min)

Area
(mm2)

Velocity
(mm/s)

Residence time
(µs)

Lateral Diameter
(µm)

0.3

0.5

10

97.6

0.976

0.4

0.5

13.33

73.4

0.979

0.5

0.5

16.67

62.0

1.032

0.6

0.5

20.00

49.7

0.994

0.7

0.5

23.33

42.7

0.996

0.8

0.5

26.67

36.7

0.980

0.9

0.5

30.00

32.6

0.980

1.0

0.5

33.33

29.4

0.980
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5.3.2 Verification of multi-photon FCS measurements in vivo
To investigate whether multiphoton excitation FCS has the desired ability to
perform flow measurements in vivo, we extended our studies to measure blood flow in the
cerebrovasculature of live animals. Initial experiments were performed using a thinned
skull preparation to enable optical penetration into the mouse brain (Figure 5.4a and b).
Animals were intravenously injected with both a high concentration label to visualize and
image the vascular architecture and a low concentration FCS tracker molecule to enable
blood flow measurements. Multi-photon imaging from 100 µm to 300 µm deep revealed
vessels ranging from capillaries (<10 µm) to much larger vessels (Figure 5.4c). To validate
our ability to record flow rates, we positioned the FCS excitation beam in the center of a
20 µm vessel and recorded photon arrival events from a single location (single pixel
measurement). Spikes in the reconstructed time versus intensity trace show clear bursts in
the fluorescence signal corresponding to FCS tracker molecules flowing through the focal
volume (Figure 5.4d). The corresponding autocorrelation G(τ) for the time trace in Figure
5.4d is shown in Figure 5.4e. The flow velocity was then calculated from the extracted
residence time and the calibrated focal diameter. These initial experiments validated our
capability to perform simultaneous multi-photon FCS and multi-photon imaging in the
brain of a live mouse and to extract velocity measurements at single pixels within any
vascular region accessible through multi-photon imaging.
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Figure 5.4 Illustration of the working principles of FCS in two-photon (2P) in vivo
microscopy.
a, Schematic of in vivo FCS measurements in blood vessels through a cranial window. The
equation shows the simple relationship between blood flow velocity and FCS measured
residence time. b, A representative 5mm thinned-skull window in a mouse hemisphere. c,
A representative image of a 3-D reconstruction of blood vessels from in vivo 2P imaging.
d, A fluorescence fluctuation time trace measured through a blood vessel in vivo. e, the
corresponding ACF (G(τ)) reveals the fluorescent molecule flow residence time in the focal
volume.
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5.3.3 CBF measurements from different size of vessels
To evaluate the robustness of our spectroscopic approach, we determined the flow
velocity in a series of vessels with diameters ranging from 5 to 20 µm. Within a large field
of view from a single frame of an x-y plane, we identified 4 branched vessels with
diameters of 5.2, 8.9, 17.8, and 21.7 µm (Figure 5.5a-c). We then used FCS to measure
flow rates in the center of each of these vessels. Vessel diameters and the corresponding
flow velocities are indicated in the schematic in Figure 5.5b. Fluorescence time traces taken
in each vessel show clear spikes (Figure 5.5d). The calculated flow velocities were
extracted from the normalized fit of autocorrelations for each fluorescence time trace
(Figure 5.5e). In line with the expected increased hydrodynamic resistance in smaller
vessels, the capillaries, with diameters of 5.2 and 8.9 µm, displayed much slower flow rates
(<1 mm/s) than the larger vessels. The scaling of flow rate with the diameter of the vessel
further validates the sensitivity of our technique.
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Figure 5.5 Measurements of blood flow velocities from different size of vessels.
a, 2P-image of fluorescently labeled cerebral vasculature from a thinned-skull preparation.
b, Diameter and blood flow velocity measurements of the vascular network traced from
(a). We observed the expected scaling of the flow rate with the diameter of the vessel. c,
Two representative fluorescence intensity time traces recorded from a large vessel (21.7
mm diameter, orange) and a capillary (5.2 mm diameter, pink) from (a). d, The
corresponding ACFs (G(τ)) show the different flow velocities in different vessels (color
matched to b).
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5.3.4 2P-FCS measurements of cross-sectional velocity profile
In addition to measuring flow rates in the center of vessels, we also measured the
hydrodynamic profile of the flow rate across vessels to compare the flow in the center to
that along the wall. We first performed multiphoton imaging to identify a vein and an
artery, and then used FCS to measure at opposite walls and at increments across the vessel
and build a flow velocity cross section (Figure 5.6a). The clearly defined shift in the
autocorrelation across each vessel verifies that in vivo FCS provides the capability to
measure subtle changes in flow rates and can map flow rates with sub-vessel resolution
(Figure 5.6). The lateral extension of the multi-photon excitation volume of ~0.98 µm
enables 5 independent pixel measurements across even the smallest vessel observed here
(~5 µm). As predicted by laminar flow, the cross-sectional velocity analysis revealed that
blood flow through the center of vessel is larger than at locations near the vessel wall.
In order to better visualize the motion of the blood flow with sub-vessel resolution,
we next used FCS to measure flow rates within the xy plane across segments of vessels.
This allowed us to build a 2-dimensional (2D) map of flow rates within a plane across the
width of the vessel which is indicated by the heat map overlaid on the segments of each
vessel (Figure 5.7a). The heat map clearly shows the higher velocity in the center of the
vessel along the entire segment. The color matched flow velocity line profiles in Figure
5.7b show same results. It further shows that the high spatial resolution of this approach
allows us to perform sub-vessel resolution measurements providing a map of the velocity
within a vessel. The corresponding autocorrelations are shown in Figure 5.7c-e.
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Figure 5.6 Measurements of cross-section blood flow velocities.
a, 2P-FCS enables measurements of sub-vessel resolution blood flow velocity. A cross
section profile of flow velocity of an artery or vein is generated by sequentially measuring
across the vessel with the FCS detection pixels indicated with orange stars (artery) or blue
circles (vein). b and d show blood velocity profiles across the width of blood vessels.
Velocities were determined at 5 points across the width of a vein (b, blue) and 6 points
across an artery (d, red). Error bars are standard errors of mean (SEM) calculated from 6
measurements at the same position. c and e are corresponding ACFs (G(τ)) for each point
across the vessel for the artery (red) and vein (blue).
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Figure 5.7 Autocorrelation curves from the heat map of blood flow rates.
a, A 2P image of a blood vessel from a 3 mm open cranial window and the corresponding
flow velocity maps in three blood vessels (traced in blue, pink, and green color). The heat
map corresponds to the flow velocity (see key: green to red, 0.5 mm/sec to 3.5 mm/sec).
The central region of the vessel exhibits a higher velocity than the near the walls. b, The
corresponding cross section blood flow velocity line profiles from a. c-e. The normalized
autocorrelation curves show the flow velocity changes for 3 separate vessels, where c, d, e
are for the blue, pink, and green line traced vessels, respectively.
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5.3.5 2D cross-sectional velocity profiles measured by 2P-FCS
To further characterize flow rates in complex vessel geometries, 2D cross-sectional
flow profiles were mapped by performing FCS at multiple points within a plane
perpendicular to the flow direction before and after a vessel branch (Figure 5.8a). We
positioned the FCS beam and monitored the flow rate of FCS tracker molecules through
the focal volume near walls at the top, bottom, and both sides within a cross-sectional
plane. We also collected data from the center of the vessel. The velocity profiles were
extracted from FCS autocorrelations from each location (Figure 5.8c, e) and represented
on the color-coded map of the cross section (Figure 5.8b and d). There was a consistent
decrease in the flow rate at the edges of the vessel. The two locations measured here were
in the same vessel before and after a branch. The branch had a significant effect on the flow
rate observed over the entire cross section where we saw roughly a 30% change in the flow
rate contralateral to the branch. This illustrates the capability of in vivo FCS to detect subtle,
anatomical changes in flow rate dynamics.
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Figure 5.8 The flow velocity profiles from 2D cross-section of the blood vessels.
a, Representative 2P image of a blood vessel with a branch. b and d, Results of twodimensional cross-section blood flow velocity profiles. Brown and orange plots
corresponding to 2D blood flow velocity profiles before and after the branch. The heat map
corresponds to the flow velocity (see key: green to red, 0.5 mm/sec to 3.5 mm/sec). c and
e, Corresponding ACFs (G(τ)) show the different flow velocities in the cross-section of the
vessel.
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5.3.6 Using 2P-FCS to monitor CBF dynamic changes
We next utilized in vivo FCS to monitor physiological dependent dynamic changes
in blood flow rates. We identified a region approximately 300 µm deep in the brain with
branched vessels. We then monitored the baseline flow rate using FCS at 2 locations
(Figure 5.9a). The heart rate was then increased by modifying the level of anesthesia while
simultaneously recording FCS measurements and monitoring the heart rate. Concurrent
with the increased heart rate, we observed a corresponding increase in the blood flow rate
at both locations (Figure 5.9b). The autocorrelation curves for the two positions (Figure
5.9c and d) also show clear shifts revealing the capability of high sensitivity measurements
for monitoring dynamic changes in flow rates.
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Figure 5.9 Blood flow dynamics at different heart rates
a, Representative 3D reconstruction of the vascular network, and the zoomed-in version of
the yellow box from the full field of view 3D image. The boxed area is the vessel that can
be seen 30µm blow the bright vessel in the 3D image. b, Representative blood flow
dynamics due to changes in heart rate at two locations indicated in a. c, and d show
representative ACFs for different heart rates. The orange and green figures correspond to
the two locations indicted in a.
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5.4

Discussions
The presented results demonstrate that the technique is capable of measuring flow

profiles at sub-vessel resolution and monitoring the dynamic changes in CBF within live
animals. This technique relies on the combination of multiphoton in vivo imaging with FCS
measurements. Two-photon excitation leads to an increasing penetration depth in live
tissue and significantly reduces scattering light, which enables the measurement deep into
vessels. FCS has an extreme sensitivity that could capture the temporal fluorescence
fluctuations. For the in vivo FCS measurements, an encountered challenge in live animal
imaging are motion artifacts. Without sufficient immobilization, movements during
respiration led to artifacts in the fluorescence time trace (Figure 5.10). This was also
observed in the subsequent autocorrelations, which showed components on the same time
scale as the animal breathing. Thus, in vivo FCS measurements required rigorous attention
to the animal restraint to eliminate breathing artifacts. In order to avoid these artifacts, we
designed and 3-D printed a custom mouse head holder, which minimized the movement of
the anesthetized mouse, and ensured the contribution of fluorescence fluctuation from flow
is much larger compared to fluctuations induced by breathing.
Besides, another major difficulty of our multicolor FCS measurements and vascular
imaging by two-photon excitation is choosing a strongly performed dye pair. We have
tested several different fluorescent probes including FITC-dextran, Rhodamine B-dextran,
CF488-dextran, CF568-dextran, Quantum dots 605, Quantum dots 655 and polymer dots.
Representative time traces and correlation curves for some of these fluorescent probes are
shown in the Figure 5.1. We have demonstrated the cy3 and rhodamine B pair also serves
similarly as cf488 with rhodamine B pair, as shown in Figure 5.11.
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Figure 5.10 The effect of breath on FCS measurements and minimizing the artifacts.
a. Example image of vasculature captured showing breathing artifacts. b. Four
representative fluorescence time traces from a cross section of one vessel. c. The rescaled
time traces showing fluorescence fluctuations over time reveal wide bursts that are
resulting from breathing artifacts in b. d. The corresponding autocorrelations identify a
second longer time scale component from breathing artifacts during FCS measurements. e.
A custom-made head restraint was used to limit the breathing motion artifacts. The restraint
was mounted on the mouse head after the cranial window preparation. The edge of the skin
was fixed by spreading the glue all over the skull. Dental cement was used to fasten the
holder on the skull. The 3d printed holder was secured between washers onto the side bars.
The 1mm thick holder has a large window in the middle, which is thick enough to stabilize
the mouse head, but not to affect the working distance of the objective.
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Figure 5.11 Blood flow measurements using Cy3-dextran 250kDa.
The vessel is imaged using Rhodamine B-dextran 500 kDa. However, the FCS
measurements dye is changed to Cy3-dextran 250 kDa to of CF488-dextran 250 kDa. a.
The 2P-image indicates the 3 points of the FCS measurements. b shows the relative cross
section blood flow velocity profile from the marked position. c. Fluorescence intensity time
traces recorded using the three positions with Cy3-dextran 250 kDa. d. The measured and
fitted autocorrelation curves from color matched time traces. e. The normalized
autocorrelation curves from d.
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5.5

Conclusion
In conclusion, we introduce an approach that adapts multi-photon in vivo FCS for

blood flow measurements with sub-vessel resolution. This technique affords real-time
measurements with high spatial and temporal resolution for mapping 2D and 3D flow
velocities and to study flow dynamics over time. The ability to measure flow velocity at
each individual pixel provides improved sensitivity (nM concentrations) as well as higher
spatial and temporal resolution over existing techniques. In vivo FCS uniquely enables the
measurement of blood flow dynamics in microvessels, allowing potential investigations of
blood brain barrier disruption, neurovascular coupling, and flow dynamics in models of
neurodegenerative diseases. The development of in vivo multi-photon FCS enables the
measurement of capillary blood flow rate changes of ~0.05 mm/sec with a spatial resolution
of 1 µm, thus providing a new capability to perform real-time measurements of cerebral
blood flow rates.
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CONCLUSION
Nicotine use disorder is one of the most common substance use disorders and
results in severe health risks. Although many studies focus on nicotine induced physiological
changes, behavioral health conditions, mechanisms under addiction, and cessation treatments,
several questions remain unanswered at present. Single-molecule imaging-based methods

have been widely used in biomedical studies, especially in the field of molecular
mechanisms. This dissertation has developed novel single-molecule imaging methods to
study membrane receptor assembly and the physiological changes under the exposure of
nicotine in order to facilitate the understanding of mechanisms involved in nicotine use
disorder.
Nicotine-induced up-regulation is well defined as changes in number, trafficking, or
stoichiometry of nAChRs. The mechanism of which, however, is unknown yet. The primary
goal of the first part of this study was to correlate structural changes with the functional
properties of nAChRs. Directed by previous cellular structural studies in our group, we
examined assemblies of α4β2 nAChR in animal brains. In this work, a novel cutting edge
single-molecule imaging method has been developed and employed to pinpoint the
stoichiometric changes of α4β2 nAChR under nicotine exposure and withdrawal. Individual
α4β2 nAChRs were embedded in nanoscale vesicles, which allowed us to isolate them from
α4 GFP knock-in mice spatially. These nanoscale vesicles were formed from endogenous cell
membranes and receptors maintained in the same environment prior to isolation. Thus, the

nanovesicles could provide a snapshot of nAChR assembly in different brain regions at the
time of vesicle formation. Combining this approach with single-molecule TIRF imaging, the
separated receptors were identified by a GFP label. Photobleaching steps corresponding to the
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number of GFP-labeled subunits were analyzed to determine the distribution and stoichiometry
of α4β2 nAChRs in animals.
In this study, single-molecule experiments were performed to examine the changes

in receptor assembly in response to the animal’s physiological condition, which allowed
us to determine the correlation of upregulation with stoichiometry. With chronic low dose
nicotine (0.7mg/kg/hr) exposure, robust changes in α4β2 nAChR stoichiometry were
observed in the cortex and hippocampus, but not in the cerebellum, hypothalamus,
midbrain, thalamus, and striatum. We also quantified α4β2 nAChR stoichiometry
throughout an animal’s withdrawal from nicotine use. The results showed that the
hippocampus took longer to return to the baseline stoichiometry as compared to the cortex.
Overall, it demonstrated that nicotine selectively alters the receptor stoichiometry in
different brain regions.
This work provides unique structural evidence of upregulation in stoichiometry
changes in vivo. It is the first time that we were able to observe receptor assembly changes
occurring in live animals at the single-molecule level. The results shown in this work have
important implications in the development of therapeutic targeting of nAChRs in vivo since
different brain regions present different responses to nicotine exposure. Linking the
different subtypes and different cell types of nAChRs to nicotine addiction will also be
significant for the discovery of therapeutic targets. Thus, this technique can be expanded
to study the assembly of nAChRs expressed in different cell types, including dopaminergic
neurons and GABAergic neurons. In addition, this technique can be applied to study the
other systems, like the assembly of many other membrane proteins in the CNS.
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The nanoscale vesicles extracted from the brain are composed of the original cell
membranes. When we extended this to cell-based studies, we determined that cell-derived
vesicles (CDVs) and extracellular vesicles (EVs) present similar compositions. Both EVs
and CDVs have been explored for therapeutic drug delivery. Surface proteins of these vesicles
are essential for the identification of the cell of origin and targets. To better characterize the

size, concentration, and surface protein of CDVs, we developed a high-throughput method
using automated screening and acquisition of fluorescence correlation spectroscopy (FCS)
approach. Measuring the size of CDVs with FCS and DLS shows that vesicles derived
from different cells have different diameters. This suggests that CDVs with different
origins may have variance in surface protein expression. Based on the changes of diffusion
time, we utilized the ht-FCS to monitor vesicle-antibody interactions, which further
allowed us to profile surface proteins of CDVs. This technique is complementary to
traditional western blot methods of protein detection, offering a sensitive and high-fidelity
analysis of proteins expressed on the vesicle surface.
The next research project focus was on the development of an innovative technique
that enables measuring physiological changes, particularly the blood flow changes related
to nicotine administration. As a highly sensitive single-molecule spectrometry technique,
FCS could also be utilized to profile flow properties. Combining multi-photon excitation
with FCS together, high-resolution blood flow velocity maps can be monitored in vivo. To
validate the application of in vivo FCS on profiling cerebral blood flow, flow velocities in
the full range of vessel size were measured in anesthetized mice. Because of the nonuniform flow features in vivo, sub-vessel resolution measurements were also performed to
provide 2D and 3D maps of flow velocities. It is also necessary to conduct flow velocity
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measurements in real-time, which allowed us to characterize and optimize flow
performance and predict blood flow regulation associated with neurons.
Due to the extreme sensitivity of in vivo FCS technique, it can be employed to
monitor the blood flow dynamic changes induced by nicotine. It can also be utilized to
establish the extent of vascular dysfunction that occurs during nicotine administration. To
date, many studies have shown that nicotine changes blood-brain barrier (BBB)
permeability [113-115]. Linking BBB disruption with vascular dysfunction together would
allow us to investigate the vascular mechanisms involved with nicotine use disorder. The
neurovascular unit (NVU), consisting of neurons, astrocytes, microglia, and many other
types of cells, facilitates CBF by neurovascular coupling [112]. With the high resolution
of in vivo imaging, we could monitor the Ca2+ transients of neurons and astrocytes.
Acquisition of blood flow dynamics with the same time scale of Ca2+ fluorescence signals
would assist in linking the neurovascular coupling with nicotine use disorder. It will also
be beneficial for finding potential therapeutic targets of nicotine-induced cerebrovascular
dysfunctions.
To fulfill the research goals of understanding the physiological effects of nicotine,
a number of novel biophysics methods were developed. 1) The ex vivo method has
provided strong structural evidence that nicotine could selectively alter the assembly of
α4β2 nAChR in live animals. 2) A high-throughput FCS has been successfully employed
to profile the surface proteins of nanovesicles extracted from cell membranes. 3) The in
vivo technique has demonstrated the capability of visualization of vasculature and
measurement of cerebral blood flow velocities. Future work will focus on applying these
approaches to facilitate the understanding of nicotine addiction mechanisms, which would
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be beneficial to the development of finding drug targets for a variety of associated
neurological disorders.
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